WO2009021868A2 - Novel piperazine amide derivatives - Google Patents

Novel piperazine amide derivatives Download PDF

Info

Publication number
WO2009021868A2
WO2009021868A2 PCT/EP2008/060213 EP2008060213W WO2009021868A2 WO 2009021868 A2 WO2009021868 A2 WO 2009021868A2 EP 2008060213 W EP2008060213 W EP 2008060213W WO 2009021868 A2 WO2009021868 A2 WO 2009021868A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
piperazin
methanone
chloro
methyl
Prior art date
Application number
PCT/EP2008/060213
Other languages
French (fr)
Other versions
WO2009021868A3 (en
Inventor
Henrietta Dehmlow
Bernd Kuhn
Ulrike Obst Sander
Stephan Roever
Tanja Schulz-Gasch
Matthew Wright
René Wyler
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40298643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009021868(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2010520529A priority Critical patent/JP5220858B2/en
Priority to BRPI0815479-1A2A priority patent/BRPI0815479A2/en
Priority to EP08786826A priority patent/EP2188266B1/en
Priority to CA2695088A priority patent/CA2695088C/en
Priority to ES08786826T priority patent/ES2393822T3/en
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to AU2008288537A priority patent/AU2008288537B2/en
Priority to CN200880103083.XA priority patent/CN101778831B/en
Priority to KR1020107005485A priority patent/KR101171507B1/en
Priority to MX2010001742A priority patent/MX2010001742A/en
Publication of WO2009021868A2 publication Critical patent/WO2009021868A2/en
Publication of WO2009021868A3 publication Critical patent/WO2009021868A3/en
Priority to ZA2010/01061A priority patent/ZA201001061B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention is concerned with novel piperazine amide derivatives of the formula
  • X is N or CH
  • Y is N or CH
  • R 1 is lower-alkyl, lower-alkoxy-lower-alkyl, halogen-lower-alkyl, lower- alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl- lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower- alkoxy, fiuoro-lower-alkyl and fiuoro-lower-alkoxy;
  • R 2 is lower-alkyl, fiuoro-lower-alkyl, lower-alkoxy-lower-alkyl, cycloalkyl, cycloalkyl- lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl-lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fiuoro- lower-alkyl, fiuoro-lower-alkoxy, lower-alkoxy-carbonyl and phenyl;
  • R 3 is aryl or heteroaryl, which aryl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, lower-alkyl, fiuoro-lower-alkyl, lower-alkoxy and fiuoro-lower-alkoxy;
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 independently from each other are hydrogen or lower- alkyl, or
  • R 4 and R 5 are bound together, or R 6 and R 7 are bound together, or R 8 and R 9 are bound together, or R 10 an R 11 are bound together, to form a ring together with the carbon atom to which they are attached, and -R 4 -R 5 -, -R 6 -R 7 -,-R 8 -R 9 - and/or -R 10 -
  • R 11 - is -(CH 2 W;
  • the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
  • LXRs Liver-X- Receptors
  • the LXRs are members of the nuclear hormone receptor superfamily.
  • the LXRs are activated by endogenous oxysterols and glucose and regulate the transcription of genes controlling multiple metabolic pathways.
  • Two subtypes, LXRalpha and LXRbeta have been described (Willy, PJ. et al., Genes Dev. 1995, 9:1033- 45; Song, C. et al., Proc Natl Acad Sci USA.1994, 91:10809-13).
  • LXRbeta is ubiquitously expressed, while LXRalpha is predominantly expressed in cholesterol metabolizing tissues such as the liver, adipose, intestine and macrophage.
  • the LXRs modulate a variety of physiological responses including regulation of cholesterol absorption, cholesterol elimination (bile acid synthesis), and transport of cholesterol from peripheral tissues via plasma lipoproteins to the liver.
  • the LXRs also appear to regulate genes involved in glucose metabolism, cholesterol metabolism in the brain, cellular differentiation and apopotosis, inflammation, and infectious diseases (Geyeregger, R. et al., Cell. MoI. Life. Sci. 2006, 63:524-539).
  • HDL-C plasma high-density lipoprotein cholesterol
  • the atheroprotective function of HDL was first highlighted almost 25 years ago and stimulated exploration of the genetic and environmental factors that influence HDL-C levels (Miller NE., Lipids 1978,13:914- 9).
  • the protective function of HDL derives from its role in a process termed reverse cholesterol transport (Forrester, J.S. and Shah, P.K., Am. J. Cardiol. 2006, 98:1542-49).
  • HDL mediates the removal of cholesterol from cells in peripheral tissues, including macrophage foam cells in the atherosclerotic lesions of the arterial wall.
  • HDL delivers its cholesterol to the liver and sterol-metabolizing organs for conversion to bile and elimination in feces.
  • LDL-C low-density lipoprotein cholesterol
  • Type II diabetes is also called non-insulin dependent diabetes mellitus (NIDDM) and has been shown to afflict 80-90 % of all diabetic patients in developed countries.
  • NIDDM non-insulin dependent diabetes mellitus
  • the pancreatic Islets of Langerhans continue to produce insulin.
  • the target organs for insulin action mainly muscle, liver and adipose tissue
  • the body continues to compensate by producing unphysiologically high levels of insulin, which ultimately decreases in the later stages of the disease, due to exhaustion and failure of pancreatic insulin-producing capacity.
  • T2D is a cardiovascular-metabolic syndrome associated with multiple co-morbidities, including insulin resistance, dyslipidemia, hypertension, endothelial dysfunction and inflammatory atherosclerosis.
  • the first line of treatment for dyslipidemia and diabetes at present generally involves a low-fat and low-glucose diet, exercise and weight loss.
  • compliance can be moderate, and as the disease progresses, treatment of the various metabolic deficiencies becomes necessary with lipid-modulating agents such as statins and fibrates for dyslipidemia, and hypoglycemic drugs, e.g. sulfonylureas, metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPAR ⁇ -agonists, for insulin resistance.
  • lipid-modulating agents such as statins and fibrates for dyslipidemia, and hypoglycemic drugs, e.g. sulfonylureas, metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPAR ⁇ -agonists, for insulin resistance.
  • LXRs are also known to control the efflux of cholesterol from the macrophage foam cell of the atherosclerotic lesion, and agonists of LXRs have been shown to be atheroprotective (Joseph, S. B. and Tontonoz, P., Curr. Opin. Pharmacol.
  • LXR modulators of LXRs would be effective treatments for the atherosclerotic disease which underlies the cardiovascular morbidity and mortality of stroke and heart disease.
  • Recent observations also suggest that there is an independent LXR mediated effect on insulin- sensitization in addition to its role in atheroprotection (Cao, G. et al., J Biol Chem. 2003, 278:1131-6).
  • LXR modulators can also show superior therapeutic efficacy on HDL- raising and atheroprotection, with additional effects on diabetes, compared to current therapies.
  • novel compounds of the present invention have been found to bind to and selectively activate LXR alpha and LXR beta or coactivate LXR alpha and LXR beta. Consequently, cholesterol absorption is reduced, HDL cholesterol is increased, and inflammatory atherosclerosis is reduced. Since multiple facets of combined dyslipidemia and cholesterol homeostasis are addressed by LXR modulators, novel compounds of the present invention have an enhanced therapeutic potential compared to the compounds already known in the art. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists.
  • Such diseases include increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, and inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, psoriasis and other inflammatory diseases of the skin, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.
  • the novel compounds of the present invention can be used for treatment of infectious diseases such as HIV, cancer and prophylaxis of age-related and inherited (e.g. Stargardt's disease) forms of macular degeneration.
  • the present invention provides the novel compounds of formula (I) which bind to LXR alpha and/or LXR beta.
  • the compounds of the present invention unexpectedly exhibit improved pharmacological properties compared to the compounds known in the art, concerning e.g. metabolic stability, selectivity, bioavailability and activity.
  • halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
  • alkyl refers to a branched or straight- chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
  • lower-alkyl refers to a branched or straight- chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
  • Lower-alkyl groups can be substituted, e.g. by 1 to 5, preferably 1 to 3, halogen. Such groups are referred to as "halogen-lower-alkyl". Examples of halogen-lower-alkyl groups are e.g. chlororethyl or iodopropyl groups.
  • fluoro-lower-alkyl refers to lower-alkyl groups which are mono- or multiply substituted with fluorine.
  • fluoro-lower-alkyl groups are e.g. CFH 2 , CF 2 H, CF 3 , CF 3 CH 2 , CF 3 (CH 2 ),, (CF 3 ) 2 CH and CF 2 H-CF 2.
  • alkenyl stands for a straight- chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms.
  • lower- alkenyl refers to a straight- chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.
  • amino signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH 2 , methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc.
  • cycloalkyl refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • alkoxy refers to the group R'-O-, wherein R' is an alkyl.
  • lower-alkoxy refers to the group R'-O-, wherein R' is a lower-alkyl.
  • fluoro-lower-alkoxy refers to the group R"-O-, wherein R" is fluoro- lower-alkyl. Examples of fluoro-lower-alkoxy groups are e.g. CFH 2 -O, CF 2 H-O, CF 3 -O, CF 3 CH 2 -O, CF 3 (CH 2 ) 2 -O, (CF 3 ) 2 CH-O, and CF 2 H-CF 2 -O.
  • alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower- alkylene groups as described below also are preferred alkylene groups.
  • lower-alkylene refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.
  • aryl alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 5 , preferably 1 to 3, substituents independently selected from the group consisting of lower- alkyl, lower- alkoxy, halogen, hydroxy, CN, CF 3 , amino, aminocarbonyl, carboxy, NO 2 , dioxo-lower- alkylene (forming e.g.
  • a benzodioxyl group lower- alkylsufonyl, aminosulfonyl, lower- alkylcarbonyl, lower- alkylcarbonyloxy, lower-alkylcarbonyl-NH, lower-alkoxycarbonyl, fluoro-lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-lower-alkyl, cycloalkyl and phenyloxy.
  • preferred substituents are halogen, lower-alkyl, fluoro-lower-alkyl, CN and lower-alkoxycarbonyl.
  • aryl groups can preferably be substituted as described below in the description and claims.
  • heterocyclyl signifies a saturated or partially unsaturated 4- to 10-membered, mono- or bicyclic heterocycle which contains one or more hetero atoms, preferably one to three, selected from nitrogen, oxygen and sulphur.
  • heterocyclyl groups are piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyranyl, morpholinyl and oxetanyl.
  • Preferred are piperidinyl and pyranyl.
  • a heterocyclyl group may optionally have a substitution pattern as described earlier in connection with the term "aryl”.
  • heterocyclyl groups can preferably be substituted as described below in the description and claims.
  • heteroaryl refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzoimidazolyl, indolyl, indazolyl, benzoisothiazolyl, benzoxazolyl, benzoisoxazolyl, 3-thieno[3,2-c]pyridin-4-yl and quinolinyl.
  • heteroaryl groups are isoxazolyl, quinolinyl, thiophenyl, pyridinyl and pyrazinyl.
  • a heteroaryl group may optionally have a substitution pattern as described earlier in connection with the term "aryl”.
  • heteroaryl groups can preferably be substituted as described below in the description and claims.
  • Compounds of formula (I) can form pharmaceutically acceptable acid addition salts.
  • pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • physiologically compatible mineral acids such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid
  • organic acids such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
  • X is N or CH
  • Y is N or CH
  • R 1 is lower-alkyl, lower-alkoxy-lower-alkyl, halogen-lower-alkyl, lower- alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl- lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower- alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
  • R 2 is lower-alkyl, fluoro-lower-alkyl, lower-alkoxy-lower-alkyl, cycloalkyl, cycloalkyl- lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl-lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro- lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl and phenyl; R 3 is aryl or heteroaryl, which aryl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, lower-alkyl, fluoro-low
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 independently from each other are hydrogen or lower- alkyl, or
  • R 4 and R 5 are bound together, or R 6 and R 7 are bound together, or R 8 and R 9 are bound together, or R 10 an R 11 are bound together, to form a ring together with the carbon atom to which they are attached, and -R 4 -R 5 -, -R 6 -R 7 -,-R 8 -R 9 - and/or -R 10 - R 11 - is -(CH 2 W;
  • the compounds of formula (I) have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, mixture of stereoisomers or as optically pure compounds.
  • Preferred compounds of the present invention are those, wherein X is N.
  • Other preferred compounds are those, wherein X is CH.
  • Y is N.
  • R 1 is lower- alkyl, aryl or aryl-lower-alkyl, wherein aryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen and lower-alkyl. More preferably, R 1 is lower-alkyl or phenyl, which phenyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl.
  • R is n-butyl, phenyl, 4-fluoro-2-methyl-phenyl, 2- methyl-phenyl, 4-fluoro-phenyl, 2-fluoro-4-methyl-phenyl or 2,4-difluoro-phenyl.
  • R 2 is lower-alkyl, aryl or heteroaryl selected from the group consisting of isoxazolyl, quinolinyl, thiophenyl and pyridinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, lower- alkoxy-carbonyl and phenyl.
  • R 2 is lower-alkyl, phenyl or heteroaryl selected from the group consisting of quinolinyl and pyridinyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkoxy and fluoro-lower-alkyl. More preferably, R 2 is methyl, isopropyl, 3-methoxy-phenyl, 3-chloro-phenyl, 2-trifluoromethyl-phenyl, quinoline-8-yl or pyridin-3-yl.
  • R 3 is aryl or a heteroaryl selected from the group consisting of pyridinyl and pyrazinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl and fluoro-lower-alkyl. More preferably, R 3 is phenyl or pyrazinyl, which phenyl or pyrazinyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl. Even more preferably, R 3 is 2,5-dimethyl-phenyl, 2-methyl-5-chloro-phenyl, 2,5-dichloro-phenyl or 3,6-dimethyl- pyrazin-2-yl.
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are hydrogen. It is also preferred that not more than two of -R 4 -R 5 -, -R 6 -R 7 -,-R 8 -R 9 - and - R 10 -R n - are bound together to form a ring. Particularly preferred compounds according to the present invention are those, wherein R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are hydrogen.
  • preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts thereof.
  • Preferred compounds of formula (I) are those selected from the group consisting of
  • Particularly preferred compounds of formula (I) are those selected from the group consisting of
  • the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
  • the invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises
  • the compounds of formula (I) can be prepared by methods known in the art or as described below in schemes 1 to 4, or in analogy to the methods described below. All starting materials are either commercially available, described in the literature or can be prepared by methods well known in the art or by methods in analogy to those described below. Unless otherwise indicated, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 ,R 8 , R 9 , R 10 , R n ,X and Y are as defined above.
  • the compounds of formula (I) might be separated into the enantiomerically pure compounds by chromatography on a chiral HPLC column, chromatography with a chiral eluant or by crystallization via diastereomeric salts.
  • R Me, Et or Bn
  • Compound 4 can be converted to the amine 5 with an excess of the corresponding amine or amino derivative NH 2 R 1 in a suitable solvent such as DMA, or DMF at RT to 100 0 C in the presence of a base such as triethylamine or N,N-diisopropylethylamine (step b).
  • a suitable solvent such as DMA, or DMF at RT to 100 0 C in the presence of a base such as triethylamine or N,N-diisopropylethylamine (step b).
  • step a Cleavage of the benzyl residue by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C
  • step a sulfonylation of the unprotected piperazine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl-diisopropylamine or triethylamine optionally in the presence of DMAP at 0 0 C to room temperature
  • step b followed by saponification of the ester by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between 0 0 C and 60 0 C.
  • Condensation of 10 and 11 to compounds of the formula (I) can be achieved by well known procedures for amide formation, using coupling reagents such as N- (3- dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDCI), 2-(benzotriazol-l- yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2- oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU), O- ( 7- azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HATU) or benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophos
  • a two-step procedure might be used: treatment of the acid 10 with oxalyl chloride in CH2CI2 in the presence of DMF or with thionyl chloride in toluene, followed by reaction with the amine 11.
  • Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC- groups (step e).
  • Compound 13 can be converted to compounds of formula (I) by treatment with halo heteroaromatics in the presence of bases such as N,N- diisopropylamine or triethyl amine in solvents such as in DMF or acetonitrile for heteroaromatic moieties R 3 .
  • bases such as N,N- diisopropylamine or triethyl amine
  • solvents such as in DMF or acetonitrile for heteroaromatic moieties R 3 .
  • R 3 aryl the Buchwald-Hartwig amination reaction may be used (e.g.
  • piperazine derivative 8 is converted into the protected compound 14 by cleavage of the benzyl residue by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C (step a), followed by N-BOC-protection with di-terf-butyl dicarbonate in solvents such as ether, THF or CH2CI2 optionally in the presence of DMAP at ambient temperature (step g).
  • solvents such as methanol, ethanol, ethyl acetate with Pd/C
  • step a N-BOC-protection with di-terf-butyl dicarbonate in solvents such as ether, THF or CH2CI2 optionally in the presence of DMAP at ambient temperature
  • step a one pot procedure may be used. Hydrogenation in methanol or ethanol with Pd/C as catalyst in the presence of di-terf-butyl dicarbonate and an amine such as triethyl amine or diisopropylethyl
  • HBTU (benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate
  • TPTU O-(l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate
  • HATU O-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate
  • BOP benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophoshate
  • BOP benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophoshate
  • BOP benzotriazol-l-yloxytris(dimethylamino)phosphonium hexa
  • a two-step procedure might be used: treatment of the acid 10 with oxalyl chloride in CH2CI2 in the presence of DMF or with thionyl chloride in toluene, followed by reaction with the amine 11.
  • Compounds 16 can be converted to compounds of the formula (I) in two steps: cleavage of the protecting group using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups or by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C for benzyl moieties (step h), followed by sulfonylation of the unprotected piperazine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl- diisopropylamine or triethylamine optionally in the presence of DMAP at 0 0 C to room temperature (step
  • Scheme 3 describes yet another synthetic route to compounds of the formula (I).
  • Monodebenzylation of compound 17 to compound 18a is achieved according to a method described by S. Gubert*, C. Braojos, A. Sacristan, J. A. Ortiz, Synthesis 1991, 318 (step a: 1) 1-chloroethyl chloroformate, dichloroethane, reflux; 2) MeOH, reflux).
  • Preparation of the amide 21 or 22 can be achieved by condensation of the acid 20 with compound 11 or lib, respectively, as described for compound 10 by using coupling reagents such as N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide- hydrochloride (EDCI), 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra- methyluronium-tetra-fluorborate (TPTU), O-(7-azabenzotriazol-l-yl)- 1,1,3,3- tetramethyluronium hexafluoro-phosphate (HATU) or benzotriazol-1- yloxytris(dimethylamino)phosphonium he
  • Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups (step e).
  • Compound 23 can be converted to compound 21 (step f) by treatment with halo heteroaromatics in the presence of bases such as N,N- diisopropylamine or triethyl amine in solvents such as in DMF or acetonitrile for heteroaromatic moieties R .
  • bases such as N,N- diisopropylamine or triethyl amine in solvents such as in DMF or acetonitrile for heteroaromatic moieties R .
  • R aryl the Buchwald-Hartwig amination reaction may be used (e.g.
  • bases such as Na 2 COs, K2CO3
  • catalysts such as tris(dibenzylideneacetone)dipalladium(0) or tetrakis(triphenylphosphine)palladium(0) in 1,2-dimethoxyethane, 1,2-diethoxyethane toluene,
  • Saponification of the ester 27 by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between O 0 C and 60 0 C yields acid 28 (step d).
  • Hydrogenation of acid 28 with Pd/C as catalyst in solvents such as methanol, ethanol, ethyl acetate or THF gives access to the desired intermediate 29 (step e), which may be separated into the cis and trans products. Further separation into the enantiomers can be achieved by chiral HPLC or by crystallization of diasteromeric salts derived from the acids 29 with chiral bases.
  • Enantiomerically enriched or pure cis piperidines may be prepared by enantioselective hydrogenation using a ruthenium catalyst such as [Ru(OAc)2 ((J?)-2-furyl)- MeOBIPHEP)], with an additive, for example triethylamine and a solvent, such as methanol for about 42 h at 20 - 80 0 C under 40 bar of hydrogen.
  • a ruthenium catalyst such as [Ru(OAc)2 ((J?)-2-furyl)- MeOBIPHEP)
  • the corresponding trans piperidines may be prepared from the cis compounds via selective epimerization of the chiral center ⁇ to the carboxyl group using a three step procedure: ester formation under Mitsunobu conditions using an alcohol, triphenylphosphine and diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD) in THF, epimerization with sodium alcoholate in toluene under reflux, followed by saponification of the ester under basic conditions by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof.
  • DEAD triphenylphosphine and diethyl azodicarboxylate
  • DIAD diisopropyl azodicarboxylate
  • Preparation of the amide 30 can be achieved by condensation of the acid 29 with compound 11 as described for compound 10 by using coupling reagents such as N- (3- dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDCI), 2-(benzotriazol-l- yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2- oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetra-fluorborate (TPTU), O- ( 7- azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluoro-phosphate (HATU) or benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluoro-pho
  • Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups (step g).
  • acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups (step g).
  • Sulfonylation of the unprotected piperidine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl-diisopropylamine or triethylamine optionally in the presence of DMAP at 0 0 C to room temperature yields the compounds of formula (I) (step h).
  • the conversion of a compound of formula (I) into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid.
  • an inorganic acid for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc.
  • organic acid such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesul
  • n number of acidic protons on the acid
  • a suitable solvent e.g. ethanol, ethanol-water mixture, tetrahydrofurane-water mixture
  • novel compounds of the present invention have been found to bind to and selectively activate LXR alpha and LXR beta or coactivate LXR alpha and LXR beta. Consequently, cholesterol absorption is reduced, HDL cholesterol is increased, and inflammatory atherosclerosis is reduced. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists.
  • Such diseases include increased lipid and cholesterol levels, particularly low HDL- cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non- insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, and inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, psoriasis and other inflammatory diseases of the skin, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.
  • the novel compounds of the present invention can be used for treatment of infectious diseases such as HIV as well as cancer and for prophylaxis of age- related and inherited (e.g. Stargardt's disease) forms of macular degeneration.
  • the invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
  • the invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly as therapeutically active substances for the treatment and/or prophylaxis of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
  • the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL- cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease, which method comprises administering a compound as defined above to a human being or animal.
  • the invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL- cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
  • the invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/ improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
  • Such medicaments comprise a compound as described above.
  • Prevention and/or treatment of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, or diabetes is the preferred indication, particularly prevention and/or treatment of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, or dyslipidemia, especially prevention and/or treatment of atherosclerotic diseases or dyslipidemia.
  • Diabetes particularly non-insulin dependent diabetes mellitus, is another preferred disease.
  • Mammalian expression vectors were constructed to express full-length human LXR alpha and LXR beta.
  • Bacterial expression vectors were constructed to produce tagged versions of the ligand binding domains (LBD) of human LXR alpha (aa 164 to 447) and human LXR beta (aa 155 to 460).
  • LBD ligand binding domains
  • the portions of the sequences encoding the LBDs were amplified from the full-length clones by PCR and then subcloned into the plasmid vectors. Final clones were verified by DNA sequence analysis (Willy et al., Genes Dev. 1995, 9:1033-45; Song et al., Proc Natl Acad Sci USA.1994, 91:10809-13).
  • LXR alpha and LXR beta receptor binding were assayed in buffer consisting of 50 mM HEPES, pH 7.4, 10 mM NaCl, 5 mM MgCl 2 .
  • buffer consisting of 50 mM HEPES, pH 7.4, 10 mM NaCl, 5 mM MgCl 2 .
  • 500 ng of LXR ⁇ -LBD or 700 ng of LXR beta-LBD proteins were bound to 80 ⁇ g or 40 ⁇ g SPA beads respectively, in a final volume of 50 ⁇ l by shaking.
  • the resulting slurry was incubated for 1 h at RT and centrifuged for 2 min at 1300 X g. The supernatant containing unbound protein was removed, and the semi-dry pellet containing the receptor-coated beads was re-suspended in 50 ⁇ l of buffer.
  • Radioligand eg. 100,000 dpm of (N-(2,2,2- trifluoroethyl) -N- [4- (2,2,2-trifluoro- 1 -hydroxy- 1 -trifluoromethylethyl) -phenyl] - benzenesulfonamide) was added, and the reaction incubated at RT for 1 h in the presence of test compounds, and then scintillation proximity counting was performed. All binding assays were performed in 96-well plates and the amount of bound ligand was measured on a Packard TopCount using OptiPlates (Packard). Dose response curves were measured within a range of concentration from 10 "10 M to 10 "4 M. Luciferase Transcriptional Reporter Gene Assays
  • Baby hamster kidney cells (BHK21 ATCC CCLlO) were grown in DMEM medium containing 10% FBS at 37°C in a 95%C>2:5%CO2 atmosphere. Cells were seeded in 6-well plates at a density of 10 5 Cells/well and then batch-transfected with either the full-length - LXR ⁇ or full-length-LXR ⁇ expression plasmids plus a reporter plasmid expressing luciferase under the control of LXR response elements. Transfection was accomplished with the Fugene 6 reagent (Roche Molecular Biochemicals) according to the suggested protocol.
  • the cells were harvested by trypsinization and seeded in 96-well plates at a density of 10 4 cells/well. After 24 hours to allow attachment of cells, the medium was removed and replaced with 100 ⁇ l of phenol red-free medium containing the test substances or control ligands (final DMSO concentration: 0.1%). Following incubation of the cells for 24 hours with substances, 50 ⁇ l of the supernatant was discarded and then 50 ⁇ l of Luciferase Constant-Light Reagent (Roche Molecular Biochemicals) was added to lyse the cells and initiate the luciferase reaction. Luminescence, as a measure of luciferase activity, was detected in a Packard TopCount. Transcriptional activation in the presence of a test substance was expressed as fold-change in luminescence compared to that of cells incubated in the absence of the substance. EC50 values were calculated using the XLfit program (ID Business Solutions Ltd. UK).
  • the compounds according to formula (I) have an activity in at least one of the above assays (EC50 or IC50) of 1 nM to 100 ⁇ M, preferably 1 nM to 10 ⁇ M, more preferably 1 nM to 1 ⁇ M.
  • the compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
  • the production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials.
  • lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules).
  • Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like.
  • Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils.
  • Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols.
  • Suitable carrier materials for topical preparations are glycerides, semi- synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
  • Usual stabilizers preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
  • the dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 2000 mg, especially about 1 to 500 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
  • the pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-200 mg, of a compound of formula I.
  • BOC t-butyloxycarbonyl
  • DEAD diethyl azodicarboxylate
  • DMF dimethylformamide
  • HBTU 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate
  • TBME terf-butyl-methyl ether
  • THF tetrahydrofuran
  • TFA trifluoroacetic acid.
  • MeOBIPHEP 1 (6,6'-Dimethoxy[l,l'-biphenyl]-2,2'-diyl)bis[bis(3,5- di-ter£-butyl-4-methoxyphenyl)phosphine)
  • Ligands are known in the art and/or can be prepared according to the examples or methods as described in EP O 398 132, WO 92/16535, EP O 104 375 or EP 0 580 331.
  • Step 1 4-(4-fluoro-2-methyl-phenyl)-piperazine-l,3-dicarboxylic acid 1-terf-butyl ester (CAS Reg. No.: [499780-10-8]) (100 mg) in DMF (2.5 mL) was treated with l-(2,5- dimethylphenyl)piperazine (62 mg), 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl- uronium hexafluoro phosphate (HBTU) (123 mg) and triethylamine (124 ⁇ L) at ambient temperature for 5h.
  • HBTU 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl- uronium hexafluoro phosphate
  • HBTU 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl- uronium hexaflu
  • Step 2 To a solution of 3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- 2-methyl-phenyl) -piperazine- 1 -carboxylic acid tert-but ⁇ ester (133 mg) in ethanol (5 mL) was added a saturated solution of hydrogen chloride in ethanol (1 mL).
  • Step 3 To a solution of [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl- phenyl) -piperazin-2-yl] -methanone hydrochloride (42 mg) in DMF (1 mL) was added 3- methoxybenzene sulfonyl chloride (21.4 mg) and triethyl amine (40 ⁇ L). The reaction mixture was stirred at ambient temperature for 2h, was diluted with ethyl acetate and washed with a saturated aqueous solution of NaHCO3. The combined organic phases were washed with water and brine, dried (Na2SO4), filtered and evaporated.
  • Step 1 To a solution of benzylamine (60.3 mL) and triethylamine (96.3 mL) in THF (800 mL) was added chloroacetyl chloride (45.8 mL) at 0 0 C. The reaction mixture was allowed to warm to room temperature over night. Additional chloroacetyl chloride (4.6 mL) was added and stirring was continued until no starting material could be detected. The reaction mixture was filtered, washed with ethyl acetate and concentrated. The crude product was crystallized from dichloromethane to yield N-benzyl-2-chloro-acetamide (71.6 g) as off- white solid.
  • Step 2 To a solution of N-benzyl-2-chloro-acetamide (20 g) in DMF (200 mL) were added 4-fluoro-2-methylaniline (13.3 mL) and N,N-diisopropylethylamine (22.2 mL). The reaction mixture was heated to 100 0 C over night, cooled to room temperature, and the mixture was diluted with ethyl acetate and washed with water. The combined inorganic phases were extracted with ethyl acetate and the combined organic phases were dried (Na2SO4), filtered and evaporated.
  • Step 3 To a solution of N-benzyl-2-(4-fluoro-2-methyl-phenylamino)-acetamide (17 g) in THF (500 mL) was added a solution of borane tetrahydrofuran complex (499.4 mL, IM in THF). The solution was heated to reflux for 4h, was concentrated and redissolved in a mixture of 2M HCl and TBME. The inorganic phase was extracted with TBME, the organic phases washed with 2M HCl. The pH of the combined inorganic phases was adjusted to pH 11 by the addition of concentrated NaOH, and the solution was extracted with TBME.
  • Step 4 To N-benzyl-N'-(4-fluoro-2-methyl-phenyl)-ethane-l,2-diamine (15.1 g) in toluene (150 mL) was added N,N-diisopropylethylamine (33.8 mL) and 2,3- dibromopropionic acid ethyl ester (25.61 mL) in toluene (350 mL). The reaction mixture was heated to 135°C for 18 h, cooled to room temperature, and the precipitated solid was removed by filtration.
  • Step 5 4-Benzyl-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester (1 g) in ethyl acetate (10 mL) was hydrogenated in the presence of 10% Pd/C (149 mg) and acetic acid (1 mL). After removal of the catalyst and evaporation of the solvent, the residue was dissolved in DMF (8 mL) and was treated with 3-chlorobenzenesulfonyl chloride (280 ⁇ L) and triethylamine (1.96 mL) at ambient temperature until no starting material could be detected by TLC.
  • Step 6 To a solution of 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester (730 mg) in tetrahydrofuran (20 mL) was added 1 M aqueous LiOH solution (16.6 mL) and methanol until a clear solution was obtained. The mixture was stirred at reflux for Ih, IM KHSO4 (20 mL) was added and the inorganic phase was extracted with ethyl acetate.
  • Step 7 In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid, l-(2,5-dimethylphenyl)-piperazine, HBTU and triethylamine in DMF was prepared [4-(3-chloro-benzenesulfonyl)-l-(4- fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- methanone as a white solid, MS: 584.7 ( [M+H, ICl] + ).
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 604.8 ( [M+H, ICl] + ).
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydro-chloride was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 624.5 ( [M+H, ICl] + ).
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(2-methylphenyl)piperazine was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- (4-o-tolyl-piperazin-l-yl)-methanone as a light yellow foam, MS: 571.2 ( [M+H, ICl] + ).
  • Steps 1-4 In analogy to example 2, steps 1-4, from benzylamine, chloroacetyl chloride, aniline and 2,3-dibromopropionic acid ethyl ester was prepared 4-benzyl-l -phenyl - piperazine-2-carboxylic acid ethyl ester as a light yellow oil, MS: 325.5 ([M+H] + ).
  • Step 5 In analogy to example 2, step 5, from 4-benzyl-l-phenyl-piperazine-2-carboxylic acid ethyl ester and 3-methoxy-benzenesulfonyl chloride was prepared 4-(3-methoxy- benzenesulfonyl)-l-phenyl-piperazine-2-carboxylic acid ethyl ester as a light yellow oil,
  • Step 6 In analogy to example 2, step 6, from 4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazine-2-carboxylic acid ethyl ester was prepared 4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazine-2-carboxylic acid as an off white solid, MS: 375.5 ([M+H] + ).
  • Step 7 In analogy to example 1, step 1, from 4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)piperazine dihydrochloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl]-methanone as a white solid, MS: 589.0 ( [M+ H, ICl] + ).
  • step 1 from 4- (3-methoxy-benzenesulfonyl)-l -phenyl - piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared [4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] - [4-(3-methoxy-benzenesulfonyl) - 1 -phenyl-piperazin- 2-yl] -methanone as a white solid, MS: 548.8 ( [M+H] + ).
  • step 1 from 4- (3-methoxy-benzenesulfonyl)-l -phenyl - piperazine-2-carboxylic acid and l-(5-chloro-2-methylphenyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl] -methanone as a white solid, MS: 568.8 ( [M+ H, ICl] + ).
  • Steps 1-4 In analogy to example 2, steps 1-4, from benzylamine, chloroacetyl chloride, o- toluidine and 2,3-dibromopropionic acid ethyl ester was prepared 4-benzyl-l-o-tolyl- piperazine-2-carboxylic acid ethyl ester as an orange oil, MS: 339.4 ([M+H] + ).
  • Step 5 In analogy to example 2, step 5, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester and 3-chlorobenzenesulfonyl chloride was prepared 4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 422.9 ([M+H, ICl] + ).
  • Step 6 In analogy to example 2, step 6, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl- piperazine-2-carboxylic acid ethyl ester was prepared 4-(3-chloro-benzenesulfonyl)-l-o- tolyl-piperazine-2-carboxylic acid as a light yellow solid, MS: 393.3 ( [M-H, ICl] " ).
  • Step 7 In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl- piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydrochloride was prepared [4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro- phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 606.6 ([M+H, ICl] + ).
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1- yl] -methanone as a light yellow solid, MS: 586.8 ( [M+H, ICl] + ).
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] - methanone as a light yellow solid, MS: 567.3 ([M+H, ICl] + ).
  • Step 1 Under argon at 0 0 C, to a solution of ethyl l,4-dibenzylpiperazine-2-carboxylate (10 g) in dichloroethane (40 mL) a solution of 1-chloroethyl chloroformate (4.73 mL) in dichloroethane (14 mL) was added dropwise over a period of 10 min. The reaction mixture was stirred for 15 minutes at 0 0 C, and then heated to reflux overnight. The solvent was evaporated and the crude material was dissolved in ethanol and heated at reflux overnight. The solvent was evaporated and the residue was dissolved in water and extracted with diethyl ether (x2) and CH2CI2 (x2).
  • Step 2 A solution of l-benzyl-piperazine-2-carboxylic acid ethyl ester (300 mg) in DMF (13 mL) was treated with triethylamine (0.5 mL) and 3-methoxybenzene sulfonyl chloride (274.6 mg) at RT for 2 hours. Water was added, and the inorganic layer was extracted with ethyl acetate (x3).
  • Step 3 In analogy to example 2, step 6, from l-benzyl-4-(3-methoxy-benzenesulfonyl)- piperazine-2-carboxylic acid ethyl ester was prepared l-benzyl-4-(3-methoxy- benzenesulfonyl)-piperazine-2-carboxylic acid, which was subjected to the next reaction without further purification. MS: 389.5 ( [M-H] " ).
  • Step 4 In analogy to example 1, step 1, from l-benzyl-4-(3-methoxy-benzenesulfonyl)- piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared [1- benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 563.5 ([M+H] + ).
  • Example 15 [l-Benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
  • Step 1 In analogy to example 1, step 1, from l,4-dibenzylpiperazine-2-carboxylic acid (CAS Reg.
  • Step 2 In analogy to example 13, steps 1-2, from (l,4-dibenzyl-piperazin-2-yl)-[4-(2,5- dimethyl-phenyl)-piperazin-l-yl]-methanone and 3-chlorobenzene sulfonyl chloride was prepared [ l-benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 567.3 ([M+H, ICl] + ).
  • Step 1 To a solution of N-l-Boc-2-piperazinecarboxylic acid methyl ester (CAS Reg. No: [129799-15-1]) (1 g) in DMF (5 mL) was added 3-chlorobenzenesulfonyl chloride (0.95 g) and triethylamine (1.71 mL). The reaction mixture was stirred at RT overnight. Water was added and the mixture was extracted with ethyl acetate (x2). The combined organic layers were washed with water (x2) and brine, were dried (Na2SC>4), filtered and evaporated.
  • Step 2 In analogy to example 2, step 6 (ambient temperature), from 4-(3-chloro- benzenesulfonyl)-piperazine-l,2-dicarboxylic acid 1-terf-butyl ester 2-methyl ester was prepared 4-(3-chloro-benzenesulfonyl)-piperazine-l,2-dicarboxylic acid l-tert-buty ⁇ ester as a white foam, MS: 403.2 ( [M-H, ICl] " ).
  • Step 3 In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-piperazine- 1,2-dicarboxylic acid 1-terf-butyl ester and l-(2,5-dimethylphenyl)-piperazine was prepared 4-(3-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)-piperazine-l- carbonyl]-piperazine-l-carboxylic acid tert-but ⁇ ester as a white foam, MS: 577.4 ( [M+H, ICl] + ).
  • Step 4 To a solution of 4-(3-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-piperazine-l-carboxylic acid tert-butyl ester (2.18 g) in ethanol (21.8 mL) was added a saturated solution of HCl in ethanol (21.8 mL) at 0 0 C. The reaction mixture was stirred at ambient temperature overnight, the solution was concentrated and the residue dissolved in a mixture of NaHCU3 solution and ethyl acetate.
  • Step 5 To a solution of [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone (100 mg) in acetone (4 mL) was added cesium carbonate (82 mg), followed by 1-bromopropane (21 ⁇ L). The reaction mixture was stirred at reflux overnight. Water was added and the reaction mixture was extracted with ethyl acetate (x2). The combined organic layers were washed with brine, dried (Na2SC>4), filtered and evaporated.
  • step 5 from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone and 1 -bromobutane was prepared [1- butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin- l-yl]-methanone as a white foam, MS: 533.4 ( [M+H, ICl] + ).
  • step 5 from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
  • step 5 from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone and 1-bromopentane was prepared [4-(3-chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 547.3 ([M+H, ICl] + ).
  • step 5 from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin- 1-yl] -methanone and l-bromo-2-methylpropane was prepared [4-(3-chloro-benzenesulfonyl)-l-isobutyl-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin- 1-yl] -methanone as a white foam, MS: 533.2 ([M+H, ICl] + ).
  • step 5 from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin- 1-yl] -methanone and (2-bromoethyl) -benzene was prepared [4-(3-chloro-benzenesulfonyl)-l-phenethyl-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin- 1-yl] -methanone as a colorless oil, MS: 581.3 ( [M+H, ICl] + ).
  • Steps 1-3 In analogy to example 17, steps 1-3, from N-l-Boc-2-piperazinecarboxylic acid methyl ester (CAS Reg. No: [129799-15-1]), 4-chlorobenzenesulfonyl chloride and 1- (2,5-dimethylphenyl)-piperazine was prepared 4-(4-chloro-benzenesulfonyl)-2-[4-(2,5- dimethyl-pheny ⁇ -piperazine-l-carbonylj-piperazine-l-carboxylic acid tert-but ⁇ ester as a light yellow foam, MS: 577.4 ( [M+H, ICl] + ).
  • Step 4 To a solution of 4-(4-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-piperazine-l-carboxylic acid tert-but ⁇ ester (1.64 g) in ethanol
  • Step 5 To a solution of [4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone hydrochloride (100 mg) in acetone (4 mL) was added cesium carbonate (254 mg), followed by 1-bromopentane (27 ⁇ L). The reaction mixture was stirred at ambient temperature for 1 h. Additional cesium carbonate (127 mg) and 1-bromopentane (14 ⁇ L) were added and stirring was continued at reflux over night. Water was added and the reaction mixture was extracted with ethyl acetate (x2).
  • step 5 from [4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl) -piperazin-l-yl]-methanone hydrochloride and 1 -bromobutane was prepared [ l-butyl-4-(4-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 533.3 ([M+H, ICl] + ).
  • the reaction mixture was stirred at 80 0 C overnight.
  • the mixture was cooled to room temperature, an aqueous solution of NaHCC>3 was added, the phases were separated, and the inorganic one was extracted with ethyl acetate (x3).
  • the combined organic layers were dried (Na2SC>4), filtered and evaporated.
  • Step 1 In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 2-chlorobenzenesulfonyl chloride was prepared 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-2- carboxylic acid ethyl ester as a yellow oil, MS: 441.1 ([M+H, ICl] + ).
  • Step 2 In analogy to example 2, step 6, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester was prepared 4-(2-chloro- benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid as a white solid, MS: 410.9 ( [M-H, ICl] " ).
  • Step 3 In analogy to example 1, step 1, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydrochloride was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 626.8 ( [M+H, ICl] + ).
  • step 1 from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid (example 25, step 2) and l-(5-chloro-orf/jo- tolyl)-piperazine, was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl] - [4- (5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone as a white solid, MS: 604.8 ( [M+H, ICl] + ).
  • step 1 from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazin-2-carboxylic acid (example 25, step 2) and l-(2,5- dimethylphenyl)-piperazine was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 584.8 ( [M+H, ICl] +
  • Step 1 In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 1-naphthalenesulfonyl chloride was prepared l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- l-sulfonyl)-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 457.3 ([M+H] + ).
  • Step 2 In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene-1-sulfonyl) -piperazine-2-carboxylic acid ethyl ester was prepared l-(4- fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazine-2-carboxylic acid as a white solid, MS: 427.0 ( [M-H] " ).
  • Step 3 In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene-1-sulfonyl) -piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)- piperazine dihydrochloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[l-(4- fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 641.2 ( [M+H, ICl] + ).
  • step 1 from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)- 4- (naphthalene- l-sulfonyl)-piperazin-2-yl] -methanone as a white solid, MS: 621.0
  • step 1 from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
  • step 1 from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(3-trifluoromethyl-pyridin-2-yl)-piperazine (CAS Reg.
  • Step 1 In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 8-quinolinesulfonyl chloride was prepared 1- (4-fluoro-2-methyl-phenyl)-4-(quinoline-8-sulfonyl)-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 458.3 ( [M + H] + ).
  • Step 2 In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl) -piperazine-2-carboxylic acid ethyl ester was prepared l-(4-fluoro-2-methyl- phenyl)-4-(quinoline-8-sulfonyl)-piperazine-2-carboxylic acid as a white solid, MS: 428.4 ( [M-H] " ).
  • Step 3 In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydro- chloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl- phenyl)-4-(quinoline-8-sulfonyl)-piperazin-2-yl] -methanone as a white solid, MS: 642.0 ( [M + H 1 ICl] + ).
  • Example 33 Example 33
  • step 1 from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-8- sulfonyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)- 4-(quinoline-8-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 621.8 ([M+H, ICl] + ).
  • step 1 from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-8- sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (quinoline-8-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 602.0 ([M+H] + ).
  • Step 1 In analogy to example 2, step 6, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester (example 10, steps 1-4) was prepared 4-benzyl-l-o-tolyl-piperazine-2- carboxylic acid as a white solid, MS: 309.3 ([M-H] " ).
  • Step 2 In analogy to example 1, step 1, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)piperazine dihydrochloride was prepared (4-benzyl-l-o- tolyl-piperazin-2-yl)-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 522.8 ( [M+H, ICl] + ).
  • Step 3 In analogy to example 2, step 5 from (4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and iso-propylsulfonyl chloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[4-(propane-2-sulfonyl)-l-o-tolyl- piperazin-2-yl] -methanone as a white foam, MS: 539.3 ([M+H, ICl] + ).
  • step 3 from (4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and 4-biphenylsulfonyl chloride was prepared [4-(biphenyl-4-sulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 649.3 ([M+H, ICl] + ).
  • step 3 from 4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and 2-(methoxycarbonyl)thiophene-3- sulfonyl chloride was prepared 3- ⁇ 3-[4-(2,5-dichloro-phenyl)-piperazine-l-carbonyl]-4- o-tolyl-piperazine-l-sulfonyl ⁇ -thiophene-2-carboxylic acid methyl ester as a white foam,
  • Step 1 In analogy to example 1, step 1 , from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-
  • Step 2 In analogy to example 17, step 4, from 4-[4-(3-chloro-benzenesulfonyl)-l-(4- fluoro-2-methyl-phenyl) -piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-but ⁇ ester was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)- piperazin-2-yl]-piperazin-l-yl-methanone as a white solid, MS: 481.0 ( [M+H, ICl] + ).
  • Step 3 [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- piperazin-1-yl-methanone (60 mg), 3-chloro-2,5-dimethylpyrazine (18.1 ⁇ L) and triethylamine (20.8 ⁇ L) in acetonitrile (1 mL) were heated to 170 0 C in the microwave. Water was added and the reaction mixture was extracted with ethyl acetate. The combined organic phases were washed with brine, dried (Na2SC>4), filtered and evaporated.
  • Step 1 In analogy to example 13, step 2, from l-benzyl-piperazine-2-carboxylic acid ethyl ester and 3-chlorobenzenesulfonyl chloride was prepared l-benzyl-4-(3-chloro- benzenesulfonyl)-piperazine-2-carboxylic acid ethyl ester as a yellow oil, MS: 423.1 ( [M+H, ICl] + ).
  • Step 2 In analogy to example 2, Step 6 , from l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carboxylic acid ethyl ester was prepared l-benzyl-4-(3-chloro- benzenesulfonyl)-piperazine-2-carboxylic acid as an off-white solid, MS: 593.0 ([M-H, ICl] " ).
  • Step 3 In analogy to example 1, step 1, from l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carboxylic acid and 1-Boc-piperazine was prepared 4-[l-benzyl-4-(3- chloro-benzenesulfonyl) -piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-but ⁇ ester as a white foam, MS: 562.8 ( [M+H, ICl] + ).
  • Step 4 In analogy to example 38, step 2, from 4-[l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-but ⁇ ester was prepared [1- benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-piperazin-l-yl-methanone as a white foam, MS: 463 ([M+H, ICl] + ).
  • Step 5 In analogy to example 38, step 3, from [l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazin-2-yl]-piperazin-l-yl-methanone and 3-chloro-2,5-dimethylpyrazine was prepared [ l-benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] -(3',6'-dimethyl-
  • Example 40 [4-(3-Chloro-phenyl)-piperidin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(propane-2- sulfonyl)-piperazin-2-yl]-methanone
  • step 1 In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and iso-propylsulfonyl chloride was prepared 1- (4-fluoro-2-methyl-phenyl)-4-(propane-2-sulfonyl)-piperazine-2-carboxylic acid ester as a colorless oil, MS: 373.1 ( [M+H, ICl] + ).
  • Step 2 In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4-(propane- 2-sulfonyl)-piperazine-2-carboxylic acid ester was prepared l-(4-fluoro-2-methyl- phenyl)-4-(propane-2-sulfonyl)-piperazine-2-carboxylic acid as a yellow solid, MS: 343.1 ( [M-H 1 ICl]-).
  • Step 3 In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(propane- 2-sulfonyl)-piperazine-2-carboxylic acid and 4-(3-chlorophenyl)-piperidine was prepared [4- (3-chloro-phenyl) -piperidin- 1 -yl] - [ 1 - (4-fluoro-2-methyl-phenyl) -A-
  • step 1 from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and 3',6'-dimethyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl (CAS Reg.
  • Step 1 Cis-4-phenylnipecotic acid hydrochloride (CAS Reg. No. [858430-42-9]) (195 mg) (three times suspended in toluene and evaporated under reduced pressure to remove water) was suspended in hexamethyldisilazane (4 mL) and refluxed for 3 h. The solution was evaporated under reduced pressure and dissolved in THF (4 mL). 3-Methoxybenzene sulfonyl chloride (0.13 mL) was added and the solution was stirred for 16 h at ambient temperature. H 2 O was added and after Ih the solvents were evaporated.
  • Step 2 In analogy to example 1, step 1, from cis-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidine-3-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared cis-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl]-methanone as a white solid (mp 192°C), MS: 548.4 ([M+H]) + .
  • Step 1 In analogy to example 1, step 1, from trans-N-Boc-4-phenyl-nipecotic acid (CAS Reg. No.: [170838-49-0]) and l-(2,5-dimethylphenyl)piperazine was prepared trans-3- [4- (2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tot-butyl ester as a white foam, MS: 478.2 ([M+H]) + .
  • Step 2 In analogy to example 22, step 4, from trans-3- [4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared trans- [4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] -(-4-phenyl-piperidin-3-yl)- methanone hydrochloride as a white foam, MS: 378.4 ([M+H]) + .
  • Step 3 In analogy to example 1, step 3, from trans-[4-(2,5-dimethyl-phenyl)-piperazin-l- yl]-(-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [trans-l-(3-chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 552.1 ( [M+H, ICl] ) + .
  • step 3 from trans-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-(- 4-phenyl-piperidin-3-yl) -methanone hydrochloride and and 3,5-dimethylisoxazole-4- sulfonyl chloride (CAS Reg.
  • Step 1 To a solution of 2-methylphenylzinc chloride ( [84109-17-1], previously prepared from otolylmagnesium chloride (44.07 mL) and zinc chloride (8.81 g) in THF (200 mL)) a mixture of 4-trifluoromethanesulfonyloxy-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) (11.4 g) in THF (90 mL) followed by tetrakis(triphenylphosphine)palladium(0) (1.02 g) was added.
  • 2-methylphenylzinc chloride [84109-17-1]
  • the reaction mixture was stirred at room temperature over night and then was quenched with ice.
  • the mixture was diluted with tert-butyl methyl ether and washed with 2 M aqueous sodium carbonate solution.
  • the aqueous phases were extracted with tert-butyl methyl ether.
  • the combined organic layers were washed with brine, dried (Na2SO4), filtered and evaporated.
  • Step 2 In analogy to example 2, step 6, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid 1 -tert-butyl ester 3-methyl ester was prepared 4-o-tolyl-5,6-dihydro- 2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester as a white solid, MS: 316.2 ( [M-H]) " .
  • Step 3 In a glove box an autoclave was charged with 4-o-tolyl-5,6-dihydro-2ff-pyridine- 1,3-dicarboxylic acid 1 -tert-butyl ester (2.5 g), [Ru(OAc) 2 ( [R) -(2-furyl) -MeOBIPHEP)] (24 mg), triethylamine (1.1 mL) and methanol (25mL). The asymmetric hydrogenation was run for 60 h at 80 0 C under 40 bar of hydrogen.
  • the methanol solution was diluted with tert- butyl methyl ether (320 mL) and extracted with 1 M aqueous sodium hydroxide solution (2x, 320 mL).
  • the aqueous layer was poured on ice, acidified with ice-cold 2 M aqueous hydrochloric acid solution to pH 1 and extracted with ethyl acetate (3x).
  • Step 4 In analogy to example 1, step 1, from (3S,4S)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester and l-(2,5-dimethylphenyl)piperazine was prepared (3S,4S)-3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperidine-l- carboxylic acid tert-but ⁇ ester as a white foam, MS: 492.3 ( [M+H] ) + .
  • Step 5 In analogy to example 22, step 4, from (3S,4S)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-but ⁇ ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-4-o-tolyl-piperidin-3-yl)- methanone hydrochloride as colorless oil, MS: 392.4 ([M+H]) + .
  • Step 6 In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-methoxybenzene- sulfonyl chloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(3- methoxy-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl] -methanone as a white foam, MS: 562.5 ([M+H]) + .
  • step 3 from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)- 4-o-tolyl-piperidin-3-yl) -methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]- [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 566.4 ( [M+H, ICl] ) + .
  • Example 48 [4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o-tolyl- piperidin-3-yl)-methanone
  • step 3 from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)- 4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o- tolyl-piperidin-3-yl)-methanone as a white foam, MS: 470.1 ([M+H]) + .
  • Step 1 In analogy to example 1, step 1, from (3S,4S)-4-phenyl-piperidine-l,3- dicarboxylic acid l-tert-but ⁇ l ester (CAS Reg. No.: [197900-77-9]) and l-(2,5- dimethylphenyl)piperazine was prepared (3S,4S)-3-[4-(2,5-dimethyl-phenyl)-piperazine- l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester as a white foam, MS:
  • Step 2 In analogy to example 22, step 4, from (3S,4S)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-phenyl-piperidin-3-yl)- methanone hydrochloride as crude product, MS: 392.4 ([M+H]) + .
  • Step 3 In analogy to example 1, step 3, from [4- (2,5-dimethyl-phenyl) -piperazin- 1-yl] -
  • Example 51 [(3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone
  • step 1 In analogy to example 1, step 1, from (3R,4R)-4-phenyl-piperidine-l,3- dicarboxylic acid 1 -tert-butyl ester (CAS Reg.
  • Step 2 In analogy to example 22, step 4, from (3R,4R)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3R,4R)-4-phenyl-piperidin-3-yl)- methanone hydrochloride, which was directly subjected to the following reaction, MS: 378.4 ([M+H, 1C1]) + .
  • Step 3 In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3R,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3R,4R)-l-(3-chloro-benzenesulfonyl)-4-phenyl- piperidin-3-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 552.2 ([M+H, 1C1]) + .
  • Step 1 In analogy to example 46, step 3, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid l-tert-but ⁇ l ester using Ru(OAc) 2 ( (S) -BITIANP as catalyst for the enantioselective hydrogenation was prepared (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid 1 -tert-butyl ester as a white solid, MS: 318.4 ([M-H]) " .
  • Step 2 To a solution of triphenylphosphine (2.66 g) in THF (30 ml) was added diethyl azodicarboxylate (1.58 mL) at 0 0 C. After 30 minutes, methanol (1.58 mL) and a solution of (3R,4R)-4-o-tolyl-piperidine-l,3-dicarboxylic acid 1 -tert-butyl ester in THF (30 mL) were added subsequently at 0-5 0 C. The reaction mixture was stirred for 3 h at room temperature. The reaction was quenched with a saturated aqueous solution of NH 4 Cl, tert-butyl methyl ether was added, and the phases were separated.
  • Step 3 A mixture of (3R,4R)-4-o-tolyl-piperidine-l,3-dicarboxylic acid l-tert-buty ⁇ ester 3-methyl ester (200 mg) and sodium methoxide (65 mg) in anhydrous toluene (6 mL) was heated at reflux over night. After cooling to room temperature the reaction mixture was quenched with water and concentrated in vacuo. The residue was dissolved in a mixture of 1,4-dioxane (3 mL) and 2 M aqueous sodium hydroxide solution (3 mL). After stirring at RT for 5 h the mixture was diluted with water and washed with two portions of tert-but ⁇ methyl ether.
  • Step 4 In analogy to example 1, step 1, from (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester and l-(2,5-dimethylphenyl)piperazine was prepared (3S,4R)-3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperidine-l- carboxylic acid tert-butyl ester as a white solid, MS: 492.1 ( [M+H] ) + .
  • Step 5 In analogy to example 22, step 4, from (3S,4R)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l -carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-o-tolyl-piperidin-3-yl)- methanone hydrochloride as a white solid, MS: 392.3 ([M+H]) + .
  • Step 6 In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-methoxybenzene- sulfonylchloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(3- methoxy-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-methanone as a white solid, MS:
  • Step 1 In analogy to example 46, steps 1-2, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 4-fluorophenylzinc bromide was prepared 4- (4-fluoro-phenyl) -
  • step 2 In analogy to example 46, step 3, from 4-(4-fluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-butyl ester using [Ru(OAc) 2 ( (R) -MeOBIPHEP)] as catalyst for the enantioselective hydrogenation was prepared (-)-(3S,4S)-4-(4-fluoro- phenyl)-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester as an off-white solid, MS: 322.5 ([M+H]) + .
  • Step 3 In analogy to example 1, step 1, from (-)-(3S,4S)-4-(4-fluoro-phenyl)-piperidine- 1,3-dicarboxylic acid l-tert-butyl ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- phenyl)-piperidine-l-carboxylic acid tert-butyl ester as a white foam, MS: 516.3 ([M+H, ICl] ) + .
  • Step 4 In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-(4-fluoro-phenyl)-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-(4-fluoro- phenyl)-piperidin-3-yl]-methanone hydrochloride as a white foam, MS: 416.4 ( [M+H, 1C1]) + .
  • Step 5 In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3- chlorobenzenesulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] ) + .
  • step 3 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(4-fluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- (trifluoromethyl)benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)- piperazin- 1 -yl] - [ (3S,4S) -4- (4-fluoro-phenyl) - 1 - (2-trifluoromethyl-benzenesulfonyl) - piperidin-3-yl] -methanone as a white foam, MS: 624.2 ([M+H, ICl] ) + .
  • step 1 from 4-(4-fluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-butyl ester using [Ru(OAc) 2 ((S)-(3,5-Xyl,4-MeO- MeOBIPHEP))] as catalyst for the enantioselective hydrogenation was prepared (3R,4R)- 4-(4-fluoro-phenyl)-piperidine-l,3-dicarboxylic acid l-tert-butyl ester as white foam, MS: 322.5 ([M-H]) "
  • Step 2 In analogy to example 52, steps 2-3, from (3R,4R)-4-(4-fluoro-phenyl)- piperidine-l,3-dicarboxylic acid l-tert-buty ⁇ ester was prepared (3S,4R)-4-(4-fluoro- phenyl)-piperidine-l,3-dicarboxylic acid l-tert-butyl ester as off-white foam, MS: 322.5 ( [M-H])-.
  • Step 3 In analogy to example 1, step 1, from (3S,4R)-4-(4-fluoro-phenyl)-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- phenyl)-piperidine-l-carboxylic acid tert-butyl ester as a light yellow foam, MS: 516.3
  • step 4 In analogy to example 22, step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-(4-fluoro-phenyl)-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro- phenyl)-piperidin-3-yl]-methanone hydrochloride as a white foam, MS: 416.4 ( [M+H, ICl] ) + .
  • Step 5 In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3- chlorobenzenesulfonyl chloride was prepared [(3S,4R)-l-(3-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] ) + .
  • step 3 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- chlorobenzenesulfonyl chloride was prepared [(3S,4R)-l-(2-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] ) + .
  • Example 57 Example 57
  • step 3 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3- sulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)- 4-(4-fluoro-phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 557.1 ([M+H, 1C1]) + .
  • Step 1 In analogy to example 46, step 1, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2-fluoro-4-methylphenylzinc bromide (CAS Reg. No. [737797- 14-7]) was prepared 4-(2-fluoro-4-methyl-phenyl)-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid 1-tert-butyl ester 3-methyl ester as light yellow oil, MS: 350.4 ( [M + H] ) + .
  • Step 2 In analogy to example 46, step 2, 4-(2-fluoro-4-methyl-phenyl)-5,6-dihydro-2H- pyridine-l,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester was prepared 4-(2-fluoro- 4-methyl-phenyl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-tert-butyl ester as a white solid, MS: 334.2 (M-H]) " .
  • Step 4 In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(2-fluoro-4-methyl- phenyl)-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl- phenyl) -piperazine- 1 -carbonyl] -4- (2-fluoro-4-methyl-phenyl) -piperidine- 1 -carboxylic acid tot-butyl ester as a white foam, MS: 530.3 ([M+H, ICl] ) + .
  • Step 5 In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2-fluoro-4-methyl-phenyl) -piperidine- 1 - carboxylic acid tert-but ⁇ ester was prepared (3S,4S) or (3R,4R)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[ 4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 430.4 ([M+H, ICl] ) + .
  • Step 6 In analogy to example 1, step 3, from (3S,4S) or (3R,4R)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R)-1- (3-chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-[4-(5-chloro- 2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 604.1 ([M+H, ICl] ) + ;
  • step 3 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2- chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R)-l-(2-chloro- benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-
  • Step 1 In analogy to example 52, steps 2-3, from (3R,4R)-4-phenyl-piperidine-l,3- dicarboxylic acid 1-tert-butyl ester (CAS Reg. No.: [197900-84-8]) was prepared (3S,4S)- 4-phenyl-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester as an off-white solid, MS: 304.3 (M-H]) " .
  • Step 2 In analogy to example 1, step 1, from 3S,4S)-4-phenyl-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-phenyl-piperidine- 1-carboxylic acid tert-butyl ester (Cas Reg. No. [652971-20-5]) as a white foam, MS: 500.5 ([M+H, 1C1]) + .
  • Step 3 In analogy to example 22, step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester and l-(5- chloro-2-methylphenyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)- piperazin-l-yl]-((3S,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride as a white foam, MS: 400.5 ([M+H, ICl] ) + .
  • Step 4 In analogy to example 1, step 3 using iPr 2 NEt as base and CH 2 Cl 2 as solvent, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-phenyl-piperidin-3-yl)- methanone hydrochloride and 3-chlorobenzene-sulfonyl chloride was prepared [(3S,4R)- l-(3-chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 572.15 ([M+H, 1C1]) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-phenyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 606.2 ( [M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-phenyl-l-(pyridine-3- sulfonyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-phenyl-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 539.3 ([M+H, 1C1]) + .
  • Step 1 In analogy to example 46, step 1, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid l-tert-butyl ester using [Ru(OAc) 2 ((S)-(BITIANP))] as catalyst for the enantioselective hydrogenation was prepared (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-butyl ester as a white foam, MS: 318.2 ( [M-H]) " .
  • Step 2 In analogy to example 52, steps 2-3, from (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester was prepared (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester as a white solid, MS: 318.4 ([M-H]) " .
  • Step 3 In analogy to example 1, step 1, from (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty ⁇ ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl- piperidine-1-carboxylic acid tert-but ⁇ ester as a white foam, MS: 512.5 ([M+H]) + .
  • Step 4 In analogy to 22 step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-but ⁇ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-o-tolyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 512.5 ( [M+H, 1C1]) + .
  • Step 5 In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4R)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 586.1 ([M+H, ICl] ) + .
  • step 4 from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-o-tolyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS
  • step 4 from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-
  • Step 1 In analogy to example 46, step 1 from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty ⁇ ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2,4-difluorophenylzinc bromide was prepared 4-(2,4-difluoro- phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty ⁇ ester as a light yellow oil, MS: 354.2 (M+H) + .
  • Step 2 In analogy to example 46, step 2, from 4- (2,4-difluoro-phenyl) -5, 6-dihydro-2ff- pyridine-l,3-dicarboxylic acid 1-terf-butyl ester 3-methyl ester was prepared 4-(2,4- difluoro-phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty ⁇ ester as a white solid, 338.1 (M-H) " .
  • Step 5 In analogy to example 1, step 1, from (3S,4R) or (3R,4S)-4-(2,4-difluoro-phenyl)- piperidine-l,3-dicarboxylic acid l-tert-buty ⁇ ester and l-(5-chloro-2-methylphenyl)- piperazine was prepared (3S,4R) or (3R,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-but ⁇ ester as a white foam, MS: 534.2 ( [M+H, 1C1]) + .
  • Step 6 In analogy to example 22, step 4, from (3S,4R) or (3R,4S)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-but ⁇ ester was prepared (3S,4R) or (3R,4S)-[4-(5-chloro-2-methyl-phenyl)- piperazin-1-yl] - [4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride as crude product, MS: 434.3 ([M+H, ICl] ) + .
  • Step 1 In analogy to example 1, step 1, from (3S,4S)-4-phenyl-piperidine-l,3- dicarboxylic acid 1-tert-butyl ester (CAS Reg. No.: [197900-77-9]) and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-but ⁇ ester as a white foam, MS: 498.5 ([M+H, ICl] ) + .
  • Step 2 In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-but ⁇ ester was prepared [4-(5-chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-phenyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 398.4 ( [M+H, ICl] ) + .
  • Step 3 In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin- l-yl]-((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-phenyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 572.2 ([M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-phenyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 606.0 ( [M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-l-(pyridine-3- sulfonyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-phenyl-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 539.2 ([M+H, 1C1]) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-propanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl- l-(propane-2-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 504.1 ( [M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-phenyl- piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l- methanesulfonyl-4-phenyl-piperidin-3-yl)-methanone as a white foam, MS: 476.1 ( [M+H, ICl] ) + .
  • Step 1 In analogy to example 1, step 1 , from (3S,4S)-4-o-tolyl-piperidine-l,3- dicarboxylic acid 1-terf-butyl ester (example 46, step 3) and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-but ⁇ ester as a white foam, MS: 512.3 ([M+H, ICl] ) + .
  • Step 2 In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-but ⁇ ester was prepared [4-(5-chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-o-tolyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 412.5 ( [M+H, ICl] ) + .
  • Step 3 In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin- l-yl]-((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 586.2 ([M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-o-tolyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl] -methanone as a white foam, MS: 620.5 ([M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l- methanesulfonyl-4-o-tolyl-piperidin-3-yl) -methanone as a white foam, MS: 490.2 ( [M+H, ICl] ) + .
  • Step 1 In analogy to example 46, steps 1-2, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty ⁇ ester 3-methyl ester (CAS Reg. No.
  • Step 3 In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl- phenyl)-piperidine-l,3-dicarboxylic acid 1-terf-butyl ester and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl- phenyl) -piperazine- 1 -carbonyl] -4- (4-fluoro-2-methyl-phenyl) -piperidine- 1 -carboxylic acid tert-butyl ester as a white foam, MS: 530.2 ( [M+H, ICl] ) + .
  • Step 4 In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (4-fluoro-2-methyl-phenyl) -piperidine- 1 - carboxylic acid tert-but ⁇ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 430.4 ([M+H, ICl] ) + .
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone
  • step 4 from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2-(trifluoromethyl)benzenesulfonyl chloride was prepared [4-(5-chloro-2- methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2-
  • Step 1 In analogy to example 46, step 1, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2,4-difluorophenylzinc bromide was prepared 4-(2,4-difluoro- phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester 3-methyl ester as a light yellow oil, MS: 354.2 ( [M+H] ) + .
  • Step 2 In analogy to example 46, step 2, from 4-(2,4-difluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-buty ⁇ ester 3-methyl ester was prepared 4-(2,4- difluoro-phenyl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester as a white solid, MS: 338.0 (M-H]) " .
  • Step 4 In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)- piperidine-l,3-dicarboxylic acid 1-ferf-butyl ester and l-(5-chloro-2-methylphenyl)- piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-but ⁇ ester as a white foam, MS: 534.2 ( [M+H, 1C1]) + .
  • Step 5 In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-but ⁇ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 434.5 ([M+H, ICl] ) + .
  • Example 87 Example 87
  • Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water.
  • the granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively.
  • the kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
  • Capsules containing the following ingredients can be manufactured in a conventional manner:
  • Talc 5.0 mg The components are sieved and mixed and filled into capsules of size 2.
  • Injection solutions can have the following composition:
  • the active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part).
  • the pH is adjusted to 5.0 by Acetic Acid.
  • the volume is adjusted to 1.0 ml by addition of the residual amount of water.
  • the solution is filtered, filled into vials using an appropriate overage and sterilized.
  • Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
  • the active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size.
  • the filled soft gelatin capsules are treated according to the usual procedures.
  • Sachets containing the following ingredients can be manufactured in a conventional manner:
  • Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
  • Flavoring additives 1.0 mg
  • the active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water.
  • the granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Abstract

The invention is concerned with novel piperazine amide derivatives of formula (I) wherein R1 to R11, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds bind to LXR alpha and LXR beta and can be used as medicaments.

Description

Case 24442
NOVEL PIPERAZINE AMIDE DERIVATIVES
The invention is concerned with novel piperazine amide derivatives of the formula
(D
Figure imgf000002_0001
wherein
X is N or CH;
Y is N or CH;
R1 is lower-alkyl, lower-alkoxy-lower-alkyl, halogen-lower-alkyl, lower- alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl- lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower- alkoxy, fiuoro-lower-alkyl and fiuoro-lower-alkoxy;
R2 is lower-alkyl, fiuoro-lower-alkyl, lower-alkoxy-lower-alkyl, cycloalkyl, cycloalkyl- lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl-lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fiuoro- lower-alkyl, fiuoro-lower-alkoxy, lower-alkoxy-carbonyl and phenyl;
R3 is aryl or heteroaryl, which aryl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, lower-alkyl, fiuoro-lower-alkyl, lower-alkoxy and fiuoro-lower-alkoxy; R4, R5, R6, R7, R8, R9, R10 and R11 independently from each other are hydrogen or lower- alkyl, or
R4 and R5 are bound together, or R6 and R7 are bound together, or R8 and R9 are bound together, or R10 an R11 are bound together, to form a ring together with the carbon atom to which they are attached, and -R4-R5-, -R6-R7-,-R8-R9- and/or -R10-
R11- is -(CH2W;
and pharmaceutically acceptable salts thereof.
Further, the invention is concerned with a process for the manufacture of the above compounds, pharmaceutical preparations which contain such compounds as well as the use of these compounds for the production of pharmaceutical preparations.
Liver-X- Receptors (LXRs) are members of the nuclear hormone receptor superfamily. The LXRs are activated by endogenous oxysterols and glucose and regulate the transcription of genes controlling multiple metabolic pathways. Two subtypes, LXRalpha and LXRbeta, have been described (Willy, PJ. et al., Genes Dev. 1995, 9:1033- 45; Song, C. et al., Proc Natl Acad Sci USA.1994, 91:10809-13). LXRbeta is ubiquitously expressed, while LXRalpha is predominantly expressed in cholesterol metabolizing tissues such as the liver, adipose, intestine and macrophage. The LXRs modulate a variety of physiological responses including regulation of cholesterol absorption, cholesterol elimination (bile acid synthesis), and transport of cholesterol from peripheral tissues via plasma lipoproteins to the liver. The LXRs also appear to regulate genes involved in glucose metabolism, cholesterol metabolism in the brain, cellular differentiation and apopotosis, inflammation, and infectious diseases (Geyeregger, R. et al., Cell. MoI. Life. Sci. 2006, 63:524-539).
About half of all patients with coronary artery disease have low concentrations of plasma high-density lipoprotein cholesterol (HDL-C). The atheroprotective function of HDL was first highlighted almost 25 years ago and stimulated exploration of the genetic and environmental factors that influence HDL-C levels (Miller NE., Lipids 1978,13:914- 9). The protective function of HDL derives from its role in a process termed reverse cholesterol transport (Forrester, J.S. and Shah, P.K., Am. J. Cardiol. 2006, 98:1542-49). HDL mediates the removal of cholesterol from cells in peripheral tissues, including macrophage foam cells in the atherosclerotic lesions of the arterial wall. HDL delivers its cholesterol to the liver and sterol-metabolizing organs for conversion to bile and elimination in feces. Studies have shown that HDL-C levels are predictive of coronary artery disease risk independently of low-density lipoprotein cholesterol (LDL-C) levels (Gordon, T. et al., Am J Med. 1977, 62:707-14). At present, the estimated age-adjusted prevalence among Americans age 20 and older who have HDL-C of less than 35 mg/dl is 16% (males) and 5.7 % (females). A substantial increase of HDL-C is currently achieved by treatment with niacin in various formulations. However, the substantial unfavorable side-effects limit the therapeutic potential of this approach.
It has been observed that as many as 90% of the 14 million diagnosed type 2 diabetic patients in the United States are overweight or obese, and a high proportion of type 2 diabetic patients have abnormal concentrations of lipoproteins. Studies have shown that the prevalence of total cholesterol > 240 mg/dl is 37% in diabetic men and 44% in women. The rates for LDL-C > 160 mg/dl are 31% and 44%, and for HDL-C < 35 mg/dl are 28% and 11%, in diabetic men and women respectively. Diabetes is a disease in which a patient's ability to control glucose levels in blood is decreased because of partial impairment in response to the action of insulin. Type II diabetes (T2D) is also called non-insulin dependent diabetes mellitus (NIDDM) and has been shown to afflict 80-90 % of all diabetic patients in developed countries. In T2D, the pancreatic Islets of Langerhans continue to produce insulin. However, the target organs for insulin action, mainly muscle, liver and adipose tissue, exhibit a profound resistance to insulin stimulation. The body continues to compensate by producing unphysiologically high levels of insulin, which ultimately decreases in the later stages of the disease, due to exhaustion and failure of pancreatic insulin-producing capacity. Thus, T2D is a cardiovascular-metabolic syndrome associated with multiple co-morbidities, including insulin resistance, dyslipidemia, hypertension, endothelial dysfunction and inflammatory atherosclerosis.
The first line of treatment for dyslipidemia and diabetes at present generally involves a low-fat and low-glucose diet, exercise and weight loss. However, compliance can be moderate, and as the disease progresses, treatment of the various metabolic deficiencies becomes necessary with lipid-modulating agents such as statins and fibrates for dyslipidemia, and hypoglycemic drugs, e.g. sulfonylureas, metformin, or insulin sensitizers of the thiazolidinedione (TZD) class of PPARγ-agonists, for insulin resistance. Recent studies provide evidence that modulators of LXRs would result in compounds with enhanced therapeutic potential, and as such, modulators of LXRs should improve the plasma lipid profile, and raise HDL-C levels (Lund, E.G. et al., Arterioscler. Thromb. Vase. Biol. 2003, 23:1169-77; Mitro, N. et al., Nature 2007, 445:219-23). LXRs are also known to control the efflux of cholesterol from the macrophage foam cell of the atherosclerotic lesion, and agonists of LXRs have been shown to be atheroprotective (Joseph, S. B. and Tontonoz, P., Curr. Opin. Pharmacol. 2003, 3:192-7). Thus, - A - modulators of LXRs would be effective treatments for the atherosclerotic disease which underlies the cardiovascular morbidity and mortality of stroke and heart disease. Recent observations also suggest that there is an independent LXR mediated effect on insulin- sensitization in addition to its role in atheroprotection (Cao, G. et al., J Biol Chem. 2003, 278:1131-6). Thus LXR modulators can also show superior therapeutic efficacy on HDL- raising and atheroprotection, with additional effects on diabetes, compared to current therapies.
The novel compounds of the present invention have been found to bind to and selectively activate LXR alpha and LXR beta or coactivate LXR alpha and LXR beta. Consequently, cholesterol absorption is reduced, HDL cholesterol is increased, and inflammatory atherosclerosis is reduced. Since multiple facets of combined dyslipidemia and cholesterol homeostasis are addressed by LXR modulators, novel compounds of the present invention have an enhanced therapeutic potential compared to the compounds already known in the art. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists. Such diseases include increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, and inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, psoriasis and other inflammatory diseases of the skin, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function. Moreover, the novel compounds of the present invention can be used for treatment of infectious diseases such as HIV, cancer and prophylaxis of age-related and inherited (e.g. Stargardt's disease) forms of macular degeneration.
Other compounds that bind to and activate LXR alpha and LXR beta have previously been suggested (e.g.: WO 03/099769). However, there is still a need for new compounds with improved properties. The present invention provides the novel compounds of formula (I) which bind to LXR alpha and/or LXR beta. The compounds of the present invention unexpectedly exhibit improved pharmacological properties compared to the compounds known in the art, concerning e.g. metabolic stability, selectivity, bioavailability and activity.
Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
In this specification the term "lower" is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s) . The term "halogen" refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
The term "alkyl", alone or in combination with other groups, refers to a branched or straight- chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms. Lower-alkyl groups as described below also are preferred alkyl groups.
The term "lower-alkyl", alone or in combination with other groups, refers to a branched or straight- chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like.
Lower-alkyl groups can be substituted, e.g. by 1 to 5, preferably 1 to 3, halogen. Such groups are referred to as "halogen-lower-alkyl". Examples of halogen-lower-alkyl groups are e.g. chlororethyl or iodopropyl groups.
The term "fluoro-lower-alkyl" refers to lower-alkyl groups which are mono- or multiply substituted with fluorine. Examples of fluoro-lower-alkyl groups are e.g. CFH2, CF2H, CF3, CF3CH2, CF3(CH2),, (CF3)2CH and CF2H-CF2.
The term "alkenyl", alone or in combination with other groups, stands for a straight- chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms. The term "lower- alkenyl" refers to a straight- chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl.
The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substitutents together forming a ring, such as, for example, -NH2, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc.
The term "cycloalkyl" refers to a monovalent carbocyclic radical of 3 to 10 carbon atoms, preferably 3 to 6 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
The term "alkoxy" refers to the group R'-O-, wherein R' is an alkyl. The term "lower-alkoxy" refers to the group R'-O-, wherein R' is a lower-alkyl. The term "fluoro-lower-alkoxy" refers to the group R"-O-, wherein R" is fluoro- lower-alkyl. Examples of fluoro-lower-alkoxy groups are e.g. CFH2-O, CF2H-O, CF3-O, CF3CH2-O, CF3(CH2)2-O, (CF3)2CH-O, and CF2H-CF2-O.
The term "alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms, more preferably up to 10 carbon atoms. Lower- alkylene groups as described below also are preferred alkylene groups. The term "lower-alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 1 to 6 or 3 to 6 carbon atoms. Straight chain alkylene or lower-alkylene groups are preferred.
The term "aryl", alone or in combination, relates to the phenyl or naphthyl group, preferably the phenyl group, which can optionally be substituted by 1 to 5 , preferably 1 to 3, substituents independently selected from the group consisting of lower- alkyl, lower- alkoxy, halogen, hydroxy, CN, CF3, amino, aminocarbonyl, carboxy, NO2, dioxo-lower- alkylene (forming e.g. a benzodioxyl group), lower- alkylsufonyl, aminosulfonyl, lower- alkylcarbonyl, lower- alkylcarbonyloxy, lower-alkylcarbonyl-NH, lower-alkoxycarbonyl, fluoro-lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-lower-alkyl, cycloalkyl and phenyloxy. Unless stated otherwise, preferred substituents are halogen, lower-alkyl, fluoro-lower-alkyl, CN and lower-alkoxycarbonyl. Furthermore, aryl groups can preferably be substituted as described below in the description and claims.
The term "heterocyclyl", alone or in combination, signifies a saturated or partially unsaturated 4- to 10-membered, mono- or bicyclic heterocycle which contains one or more hetero atoms, preferably one to three, selected from nitrogen, oxygen and sulphur. Examples of such heterocyclyl groups are piperidinyl, piperazinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, pyranyl, morpholinyl and oxetanyl. Preferred are piperidinyl and pyranyl. A heterocyclyl group may optionally have a substitution pattern as described earlier in connection with the term "aryl". Furthermore, heterocyclyl groups can preferably be substituted as described below in the description and claims.
The term "heteroaryl" refers to an aromatic 5 to 6 membered monocyclic ring or 9 to 10 membered bicyclic ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur, such as furyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiophenyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzoimidazolyl, indolyl, indazolyl, benzoisothiazolyl, benzoxazolyl, benzoisoxazolyl, 3-thieno[3,2-c]pyridin-4-yl and quinolinyl. Preferred heteroaryl groups are isoxazolyl, quinolinyl, thiophenyl, pyridinyl and pyrazinyl. A heteroaryl group may optionally have a substitution pattern as described earlier in connection with the term "aryl". Furthermore, heteroaryl groups can preferably be substituted as described below in the description and claims.
Compounds of formula (I) can form pharmaceutically acceptable acid addition salts. Examples of such pharmaceutically acceptable salts are salts of compounds of formula (I) with physiologically compatible mineral acids, such as hydrochloric acid, sulphuric acid, sulphurous acid or phosphoric acid; or with organic acids, such as methanesulphonic acid, p-toluenesulphonic acid, acetic acid, lactic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid.
In detail, the present invention relates to compounds of formula (I)
Figure imgf000008_0001
wherein
X is N or CH;
Y is N or CH;
R1 is lower-alkyl, lower-alkoxy-lower-alkyl, halogen-lower-alkyl, lower- alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl- lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower- alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
R2 is lower-alkyl, fluoro-lower-alkyl, lower-alkoxy-lower-alkyl, cycloalkyl, cycloalkyl- lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl-lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro- lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl and phenyl; R3 is aryl or heteroaryl, which aryl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, CN, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and fluoro-lower-alkoxy;
R4, R5, R6, R7, R8, R9, R10 and R11 independently from each other are hydrogen or lower- alkyl, or
R4 and R5 are bound together, or R6 and R7 are bound together, or R8 and R9 are bound together, or R10 an R11 are bound together, to form a ring together with the carbon atom to which they are attached, and -R4-R5-, -R6-R7-,-R8-R9- and/or -R10- R11- is -(CH2W;
and pharmaceutically acceptable salts thereof.
Compounds of formula (I) are individually preferred and physiologically acceptable salts thereof are individually preferred, with the compounds of formula (I) being particularly preferred.
The compounds of formula (I) have one or more asymmetric C atoms and can therefore exist as an enantiomeric mixture, mixture of stereoisomers or as optically pure compounds.
Preferred compounds of the present invention are those, wherein X is N. Other preferred compounds are those, wherein X is CH. Furthermore, it is preferred that Y is N.
Other preferred compounds of the present invention are those, wherein R1 is lower- alkyl, aryl or aryl-lower-alkyl, wherein aryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen and lower-alkyl. More preferably, R1 is lower-alkyl or phenyl, which phenyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl. Even more preferably, R is n-butyl, phenyl, 4-fluoro-2-methyl-phenyl, 2- methyl-phenyl, 4-fluoro-phenyl, 2-fluoro-4-methyl-phenyl or 2,4-difluoro-phenyl.
Another preferred embodiment of the present invention relates to compounds of formula (I) as described above, wherein R2 is lower-alkyl, aryl or heteroaryl selected from the group consisting of isoxazolyl, quinolinyl, thiophenyl and pyridinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, lower- alkoxy-carbonyl and phenyl. Preferably, R2 is lower-alkyl, phenyl or heteroaryl selected from the group consisting of quinolinyl and pyridinyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkoxy and fluoro-lower-alkyl. More preferably, R2 is methyl, isopropyl, 3-methoxy-phenyl, 3-chloro-phenyl, 2-trifluoromethyl-phenyl, quinoline-8-yl or pyridin-3-yl.
Furthermore, it is preferred, that R3 is aryl or a heteroaryl selected from the group consisting of pyridinyl and pyrazinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl and fluoro-lower-alkyl. More preferably, R3 is phenyl or pyrazinyl, which phenyl or pyrazinyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl. Even more preferably, R3 is 2,5-dimethyl-phenyl, 2-methyl-5-chloro-phenyl, 2,5-dichloro-phenyl or 3,6-dimethyl- pyrazin-2-yl.
Furthermore, it is preferred that at least 4 of R4, R5, R6, R7, R8, R9, R10 and R11 are hydrogen. It is also preferred that not more than two of -R4-R5-, -R6-R7-,-R8-R9- and - R10-Rn- are bound together to form a ring. Particularly preferred compounds according to the present invention are those, wherein R4, R5, R6, R7, R8, R9, R10 and R11 are hydrogen.
In particular, preferred compounds are the compounds of formula (I) described in the examples as individual compounds as well as pharmaceutically acceptable salts thereof.
Preferred compounds of formula (I) are those selected from the group consisting of
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl] - [ l-(4-fluoro-2-methyl-phenyl)-4-(3-methoxy- benzenesulfonyl) -piperazin-2-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl] - [4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] - [4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] - [4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone,
(-)- [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] - [4- (2,5-dichloro-phenyl) -piperazin- 1-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(4-o-tolyl- piperazin- 1 -yl) -methanone,
[4-(2,5-Dichloro-phenyl) -piperazin- 1-yl] - [4-(3-methoxy-benzenesulfonyl)-l -phenyl - piperazin-2-yl] -methanone, [4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone,
[ l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
(-)- [ l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone, [ l-Benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Benzyl-4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-propyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone,
[ l-Butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-isobutyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-phenethyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(4-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone,
[ l-Butyl-4-(4-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(4-Chloro-benzenesulfonyl)-l-phenyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone, [4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone, [l-(4-Fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazin-2-yl]-[4-(3- trifluoromethyl-pyridin-2-yl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-
8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (quinoline-8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-
8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dichloro-phenyl) -piperazin- 1-yl] - [4-(propane-2-sulfonyl)-l-o-tolyl-piperazin-2- yl] -methanone, [4-(Biphenyl-4-sulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-
1-yl] -methanone,
3-{3-[4-(2,5-Dichloro-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperazine-l-sulfonyl}- thiophene-2-carboxylic acid methyl ester,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(3', 6'- dimethyl-2,3,5,6-tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
[l-Benzyl-4-(3-chloro-benzenesulfonyl) -piperazin-2-yl] -(3', 6'-dimethyl-2,3, 5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
[4-(3-Chloro-phenyl)-piperidin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(propane-2- sulfonyl) -piperazin-2-yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
Cis-[4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [-l-(3-methoxy-benzenesulfonyl) -4- phenyl-piperidin-3-yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl] -methanone,
[Trans- l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone, [Trans-l-(3,5-Dimethyl-isoxazole-4-sulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(3-methoxy-benzenesulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone, [(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- l-yl]-((3S,4S)-l -methanesulfonyl-4-o-tolyl- piperidin-3-yl) -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- l-yl]-((3S,4S)-l -methanesulfonyl-4-phenyl- piperidin-3-yl) -methanone,
[(3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone, [4-(2,5-Dimethyl-phenyl) -piperazin- l-yl]-[(3S,4R) -1 -(3-methoxy-benzenesulfonyl) -4-o- tolyl-piperidin-3-yl] -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-(4-fluoro-phenyl)-l-(2- trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[(3S,4R)-l-(2-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl) -piperidin-3-yl] -[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro-phenyl)-l-
(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
[(3S,4S) or (3R,4R)-l-(2-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl] -[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone, (3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(propane-2-sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2- methyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-phenyl-l-(pyridine-3- sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-o-tolyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(pyridine-3-sulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone,
[(3S,4R) or (3R,4S) -l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
(3S,4R) or (3R,4S)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2,4-difluoro- phenyl) -l-(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(pyridine-3- sulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(propane-2- sulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-phenyl- piperidin-3-yl) -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-o-tolyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(pyridine-3-sulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o-tolyl- piperidin-3-yl) -methanone,
[(3S,4S) or (3R,4R) -l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-2-methyl-phenyl)- piperidin-3-yl] -[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)-l-methanesulfonyl-piperidin-3-yl]-methanone, [(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R)4R)-4-(2,4-difluoro- phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R)4R)-4-(2,4-difluoro- phenyl) -l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro- phenyl) - 1 -methanesulfonyl-piperidin-3-yl] -methanone, and
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro- phenyl) - 1 - (propane-2-sulfonyl) -piperidin-3-yl] -methanone, and pharmaceutically acceptable salts thereof.
Particularly preferred compounds of formula (I) are those selected from the group consisting of
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(3-methoxy- benzenesulfonyl) -piperazin-2-yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -[4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone,
[ l-Butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-
8-sulfonyl) -piperazin-2-yl] -methanone, [4-(2,5-Dichloro-phenyl) -piperazin- 1-yl]- [4- (propane-2-sulfonyl) -1 -o-tolyl-piperazin-2- yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(3', 6'- dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl) -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- l-yl]-[(3S,4R)-l-(3-methoxy-benzenesulfonyl)-4-o- tolyl-piperidin-3-yl]-methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro-phenyl)-l- (pyridine-3-sulfonyl)-piperidin-3-yl]-methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
(3S)4R) or (3R,4S)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2,4-difluoro- phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl] -methanone, and [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro- phenyl) - 1 -methanesulfonyl-piperidin-3-yl] -methanone, and pharmaceutically acceptable salts thereof.
It will be appreciated that the compounds of general formula (I) in this invention may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compound in vivo.
The invention further relates to a process for the manufacture of compounds of formula (I) as defined above, which process comprises
a) reacting a compound of formula (II)
Figure imgf000017_0001
with a compound of formula (III)
Figure imgf000017_0002
(HI) ,
or
b) reacting a compound of formula (IV)
Figure imgf000017_0003
(IV) with a compound R2SO2Cl, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and Y are as defined above.
The reactions given above can be carried out under conditions well known to the person skilled in the art, e.g. as described below in context with schemes 2, 3 and 4. The present invention also relates to compounds of formula (I) as defined above, when prepared by a process as described above.
The compounds of formula (I) can be prepared by methods known in the art or as described below in schemes 1 to 4, or in analogy to the methods described below. All starting materials are either commercially available, described in the literature or can be prepared by methods well known in the art or by methods in analogy to those described below. Unless otherwise indicated, R1, R2, R3, R4, R5, R6, R7,R8, R9, R10, Rn,X and Y are as defined above.
As will be understood by those skilled in the art, for the preparation of enantiomerically pure products, enantiomerically pure starting materials should be used.
In addition the compounds of formula (I) might be separated into the enantiomerically pure compounds by chromatography on a chiral HPLC column, chromatography with a chiral eluant or by crystallization via diastereomeric salts.
Scheme 1: X=N
Figure imgf000019_0002
R = Me, Et or Bn
The preparation of the starting materials for piperazine derivatives of formula (I) in which X = N is depicted in scheme 1. The synthesis starts from chloro-acetyl chloride 2 and benzylamine 3 which are converted to N-benzyl-2-chloro-acetamide 4 in the presence of bases such as triethylamine, N,N-diisopropylethylamine or N-ethyl morpholine in solvents such as ether or tetrahydrofuran at room temperature (step a).
Compound 4 can be converted to the amine 5 with an excess of the corresponding amine or amino derivative NH2R1 in a suitable solvent such as DMA, or DMF at RT to 1000C in the presence of a base such as triethylamine or N,N-diisopropylethylamine (step b).
Reduction of compound 5 with borane tetrahydrofuran complex yields amine 6 which is converted to the piperazine derivatives 8 and 9 on treatment with 2,3-dibromopropionic acid esters 7 in the presence of bases such as triethylamine or N,N-diisopropylethylamine in toluene at reflux (steps c,d).
Scheme 2: X=N
Figure imgf000020_0001
In scheme 2 the synthesis of compounds of the general formula (I) with X = N from intermediate 8 is described. Compound 8 may be transferred into the acid 10 in 3 steps: Cleavage of the benzyl residue by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C (step a), sulfonylation of the unprotected piperazine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl-diisopropylamine or triethylamine optionally in the presence of DMAP at 00C to room temperature (step b), followed by saponification of the ester by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between 0 0C and 60 0C.
Condensation of 10 and 11 to compounds of the formula (I) can be achieved by well known procedures for amide formation, using coupling reagents such as N- (3- dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDCI), 2-(benzotriazol-l- yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2- oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU), O- ( 7- azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HATU) or benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophoshate (BOP) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N-methylmorpholine optionally in the presence of 4-dimethylamino-pyridine or 1-hydroxybenzo-triazole (HOBt) in solvents such as dichloromethane, dimethylformamide, dimethylacetamide or dioxane at temperatures between 0 0C and ambient temperature (step d). Alternatively, a two-step procedure might be used: treatment of the acid 10 with oxalyl chloride in CH2CI2 in the presence of DMF or with thionyl chloride in toluene, followed by reaction with the amine 11. Alternatively acid 10 can be condensed with an amine lib (for Y=N) to yield the protected compound 12. Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC- groups (step e). Compound 13 can be converted to compounds of formula (I) by treatment with halo heteroaromatics in the presence of bases such as N,N- diisopropylamine or triethyl amine in solvents such as in DMF or acetonitrile for heteroaromatic moieties R3. For compounds with R3 = aryl the Buchwald-Hartwig amination reaction may be used (e.g. aryl-LG (LG = Br, Cl, I, triflate), Pd(OAc)2, 2- (dicyclohexylphosphino)biphenyl, NaOfBu in toluene or tris(dibenzylideneacetone)dipalladium, 2,8,9-triisobutyl-2,5,8,9-tetraaza-l- phosphabicyclo [3.3.3] undecane, sodium tert butylate in toluene).
In an alternative route piperazine derivative 8 is converted into the protected compound 14 by cleavage of the benzyl residue by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C (step a), followed by N-BOC-protection with di-terf-butyl dicarbonate in solvents such as ether, THF or CH2CI2 optionally in the presence of DMAP at ambient temperature (step g). Alternatively a one pot procedure may be used. Hydrogenation in methanol or ethanol with Pd/C as catalyst in the presence of di-terf-butyl dicarbonate and an amine such as triethyl amine or diisopropylethyl amine yields compound 14 directly. Saponification of the ester 14 or 8 by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between 0 0C and 60 0C yields the acid 15 (step c). Condensation of 15 and 11 to amides 16 can be achieved as described for compound 10 by known prodedures of amide formation, using coupling reagents such as N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDCI), 2-
(benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O- (l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetrafluorborate (TPTU), O-(7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate (HATU) or benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluorophoshate (BOP) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N- methylmorpholine optionally in the presence of 4-dimethylamino-pyridine or 1- hydroxybenzo-triazole (HOBt) in solvents such as dichloromethane, dimethylformamide, dimethylacetamide or dioxane at temperatures between 0 0C and ambient temperature (step d). Alternatively, a two-step procedure might be used: treatment of the acid 10 with oxalyl chloride in CH2CI2 in the presence of DMF or with thionyl chloride in toluene, followed by reaction with the amine 11. Compounds 16 can be converted to compounds of the formula (I) in two steps: cleavage of the protecting group using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups or by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C for benzyl moieties (step h), followed by sulfonylation of the unprotected piperazine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl- diisopropylamine or triethylamine optionally in the presence of DMAP at 00C to room temperature (step b).
Scheme 3: For X=N
Figure imgf000022_0001
22 21 (I)
23 PG"=H
Scheme 3 describes yet another synthetic route to compounds of the formula (I). Monodebenzylation of compound 17 to compound 18a is achieved according to a method described by S. Gubert*, C. Braojos, A. Sacristan, J. A. Ortiz, Synthesis 1991, 318 (step a: 1) 1-chloroethyl chloroformate, dichloroethane, reflux; 2) MeOH, reflux). Sulfonylation of the unprotected piperazine 18a or 18b with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl- diisopropylamine or triethylamine optionally in the presence of DMAP at 00C to room temperature (step b), followed by saponification of the ester by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between 0 0C and 60 0C provides acid 20 (step c). Preparation of the amide 21 or 22 can be achieved by condensation of the acid 20 with compound 11 or lib, respectively, as described for compound 10 by using coupling reagents such as N-(3-dimethylaminopropyl)-N'-ethyl-carbodiimide- hydrochloride (EDCI), 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2-oxo-l-pyridyl)-N,N,N,N-tetra- methyluronium-tetra-fluorborate (TPTU), O-(7-azabenzotriazol-l-yl)- 1,1,3,3- tetramethyluronium hexafluoro-phosphate (HATU) or benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluoro-phoshate (BOP) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N-methylmorpholine optionally in the presence of 4 -dimethylamino- pyridine or 1-hydroxybenzo-triazole (HOBt) in solvents such as dichloromethane, dimethylformamide, dimethylacetamide or dioxane at temperatures between 0 0C and ambient temperature (step d). Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups (step e). Compound 23 can be converted to compound 21 (step f) by treatment with halo heteroaromatics in the presence of bases such as N,N- diisopropylamine or triethyl amine in solvents such as in DMF or acetonitrile for heteroaromatic moieties R . For compounds with R = aryl the Buchwald-Hartwig amination reaction may be used (e.g. Pd(OAc)2, 2-(dicyclohexylphosphino)biphenyl, NaOfBu in toluene or tris(dibenzylideneacetone)dipalladium, 2,8,9-triisobutyl-2,5,8,9- tetraaza-1-phosphabicyclo [3.3.3] undecane, sodium tert butylate in toluene). Cleavage of the benzyl residue by hydrogenation in solvents such as methanol, ethanol, ethyl acetate with Pd/C (step h), followed by alkylation with RX-LG' (LC = leaving group such as Cl, Br, I, mesylate, tosylate or triflate) in the presence of a base such as potassium carbonate or cesium carbonate in a solvent such as acetone, DMF or DMA yields compounds (I). For compounds with R1 = aryl the Buchwald-Hartwig amination reaction may be used (e.g. aryl-LG (LG = Br, Cl, I, triflate), Pd(OAc)2, 2-(dicyclohexylphosphino)biphenyl, NaOfBu in toluene or tris(dibenzylideneacetone)dipalladium, 2,8,9-triisobutyl-2,5,8,9- tetraaza-1-phosphabicyclo [3.3.3] undecane, sodium tert butylate in toluene). Scheme 4: For X= C
Figure imgf000024_0001
24 25 26 27
Figure imgf000024_0002
In scheme 4 the preparation of compounds of the formula (I) with X=C is described. Starting from commercially available 24, cleavage of the benzyl residue by hydrogenation in methanol or ethanol with Pd/C as catalyst in the presence of di-tert- butyl dicarbonate and an amine such as triethyl amine of diisopropylethyl amine yields the compound 25 (step a). The enol triflate 26 can be prepared from 25 by treatment with N-phenyltrifluoromethanesulfonimide in the presence of bases such as NaH, KH or NaN(TMS)2 in solvents such as ether, THF or DMF (step b). Palladium catalyzed cross- coupling of enol triflate 26 with organic zinc halides R1ZnBr or R1ZnCl in THF, DMF or mixtures thereof at 65 0C in the presence of bis(dibenzylideneacetone)palladium(0) [Pd(dba)2] and bis(diphenylphosphino)ferrocene (dppf) gives compound 27. Alternatively, R^oronic acids in the presence of LiCl, bases such as Na2COs, K2CO3, and catalysts such as tris(dibenzylideneacetone)dipalladium(0) or tetrakis(triphenylphosphine)palladium(0) in 1,2-dimethoxyethane, 1,2-diethoxyethane toluene, or THF, or R^tannes in the presence of tris(dibenzylideneacetone)dipalladium(0) or tetrakis(triphenylphosphine)palladium(0) in solvents such as THF, ether or toluene can be used (step c). Saponification of the ester 27 by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof at temperatures between O 0C and 60 0C yields acid 28 (step d). Hydrogenation of acid 28 with Pd/C as catalyst in solvents such as methanol, ethanol, ethyl acetate or THF gives access to the desired intermediate 29 (step e), which may be separated into the cis and trans products. Further separation into the enantiomers can be achieved by chiral HPLC or by crystallization of diasteromeric salts derived from the acids 29 with chiral bases. Enantiomerically enriched or pure cis piperidines (R1=aryl,heteroaryl) may be prepared by enantioselective hydrogenation using a ruthenium catalyst such as [Ru(OAc)2 ((J?)-2-furyl)- MeOBIPHEP)], with an additive, for example triethylamine and a solvent, such as methanol for about 42 h at 20 - 80 0C under 40 bar of hydrogen. The corresponding trans piperidines may be prepared from the cis compounds via selective epimerization of the chiral center α to the carboxyl group using a three step procedure: ester formation under Mitsunobu conditions using an alcohol, triphenylphosphine and diethyl azodicarboxylate (DEAD) or diisopropyl azodicarboxylate (DIAD) in THF, epimerization with sodium alcoholate in toluene under reflux, followed by saponification of the ester under basic conditions by treatment with sodium hydroxide or lithium hydroxide in a solvent such as water, methanol, ethanol, tetrahydrofuran or mixtures thereof.
Preparation of the amide 30 can be achieved by condensation of the acid 29 with compound 11 as described for compound 10 by using coupling reagents such as N- (3- dimethylaminopropyl)-N'-ethyl-carbodiimide-hydrochloride (EDCI), 2-(benzotriazol-l- yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate (HBTU), O-(l,2-dihydro-2- oxo-l-pyridyl)-N,N,N,N-tetra-methyluronium-tetra-fluorborate (TPTU), O- ( 7- azabenzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluoro-phosphate (HATU) or benzotriazol-l-yloxytris(dimethylamino)phosphonium hexafluoro-phoshate (BOP) in the presence of a base such as ethyl-diisopropyl-amine, triethylamine, N- methylmorpholine optionally in the presence of 4-dimethylamino-pyridine or 1- hydroxybenzo-triazole (HOBt) in solvents such as dichloromethane, dimethylformamide, dimethylacetamide or dioxane at temperatures between 0 0C and ambient temperature (step f). Cleavage of the protecting group (PG) can be achieved using acidic conditions such as TFA in CH2CI2 or HCl in dioxane for BOC-groups (step g). Sulfonylation of the unprotected piperidine with sulfonyl chlorides in solvents such as dichloromethane, THF, DMF or dioxane with bases such as N-ethyl-diisopropylamine or triethylamine optionally in the presence of DMAP at 00C to room temperature yields the compounds of formula (I) (step h).
The conversion of a compound of formula (I) into a pharmaceutically acceptable salt can be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, or other inorganic acids such as sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. One method to form such a salt is e.g. by addition of 1/n equivalents of the acid, wherein n = number of acidic protons on the acid, to a solution of the compound in a suitable solvent (e.g. ethanol, ethanol-water mixture, tetrahydrofurane-water mixture) and removal of the solvent by evaporation or lyophilisation.
Insofar as their preparation is not described in the examples, the compounds of formula (I) as well as all intermediate products can be prepared according to analogous methods or according to the methods set forth above. Starting materials are commercially available or known in the art.
As described above, the novel compounds of the present invention have been found to bind to and selectively activate LXR alpha and LXR beta or coactivate LXR alpha and LXR beta. Consequently, cholesterol absorption is reduced, HDL cholesterol is increased, and inflammatory atherosclerosis is reduced. They can therefore be used in the treatment and prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists. Such diseases include increased lipid and cholesterol levels, particularly low HDL- cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non- insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, and inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, psoriasis and other inflammatory diseases of the skin, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function. Moreover, the novel compounds of the present invention can be used for treatment of infectious diseases such as HIV as well as cancer and for prophylaxis of age- related and inherited (e.g. Stargardt's disease) forms of macular degeneration.
The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.
The invention likewise embraces compounds as described above for use as therapeutically active substances, especially as therapeutically active substances for the treatment and/or prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly as therapeutically active substances for the treatment and/or prophylaxis of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease. In another preferred embodiment, the invention relates to a method for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL- cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease, which method comprises administering a compound as defined above to a human being or animal.
The invention also embraces the use of compounds as defined above for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL- cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
The invention also relates to the use of compounds as described above for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/ improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease. Such medicaments comprise a compound as described above.
Prevention and/or treatment of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, dyslipidemia, or diabetes is the preferred indication, particularly prevention and/or treatment of increased lipid levels, increased cholesterol levels, atherosclerotic diseases, or dyslipidemia, especially prevention and/or treatment of atherosclerotic diseases or dyslipidemia. Diabetes, particularly non-insulin dependent diabetes mellitus, is another preferred disease.
The following tests were carried out in order to determine the activity of the compounds of the present invention. Background information on the performed assays can be found in: Nichols JS et al. "Development of a scintillation proximity assay for peroxisome proliferator-activated receptor gamma ligand binding domain", Anal Biochem. 1998, 257: 112-119.
Mammalian expression vectors were constructed to express full-length human LXR alpha and LXR beta. Bacterial expression vectors were constructed to produce tagged versions of the ligand binding domains (LBD) of human LXR alpha (aa 164 to 447) and human LXR beta (aa 155 to 460). To accomplish this, the portions of the sequences encoding the LBDs were amplified from the full-length clones by PCR and then subcloned into the plasmid vectors. Final clones were verified by DNA sequence analysis (Willy et al., Genes Dev. 1995, 9:1033-45; Song et al., Proc Natl Acad Sci USA.1994, 91:10809-13).
Induction, expression, and purification of LBD proteins were performed in E. coli strain BL21 (pLysS) cells by standard methods (Ref: Current Protocols in Molecular Biology, Wiley Press, edited by Ausubel et al).
Radioligand Binding Assay
LXR alpha and LXR beta receptor binding were assayed in buffer consisting of 50 mM HEPES, pH 7.4, 10 mM NaCl, 5 mM MgCl2. For each 96-well reaction, 500 ng of LXRα-LBD or 700 ng of LXR beta-LBD proteins were bound to 80 μg or 40 μg SPA beads respectively, in a final volume of 50 μl by shaking. The resulting slurry was incubated for 1 h at RT and centrifuged for 2 min at 1300 X g. The supernatant containing unbound protein was removed, and the semi-dry pellet containing the receptor-coated beads was re-suspended in 50 μl of buffer. Radioligand (eg. 100,000 dpm of (N-(2,2,2- trifluoroethyl) -N- [4- (2,2,2-trifluoro- 1 -hydroxy- 1 -trifluoromethylethyl) -phenyl] - benzenesulfonamide)) was added, and the reaction incubated at RT for 1 h in the presence of test compounds, and then scintillation proximity counting was performed. All binding assays were performed in 96-well plates and the amount of bound ligand was measured on a Packard TopCount using OptiPlates (Packard). Dose response curves were measured within a range of concentration from 10"10 M to 10"4 M. Luciferase Transcriptional Reporter Gene Assays
Baby hamster kidney cells (BHK21 ATCC CCLlO) were grown in DMEM medium containing 10% FBS at 37°C in a 95%C>2:5%CO2 atmosphere. Cells were seeded in 6-well plates at a density of 105 Cells/well and then batch-transfected with either the full-length - LXRα or full-length-LXRβ expression plasmids plus a reporter plasmid expressing luciferase under the control of LXR response elements. Transfection was accomplished with the Fugene 6 reagent (Roche Molecular Biochemicals) according to the suggested protocol. Six hours following transfection, the cells were harvested by trypsinization and seeded in 96-well plates at a density of 104 cells/well. After 24 hours to allow attachment of cells, the medium was removed and replaced with 100 μl of phenol red-free medium containing the test substances or control ligands (final DMSO concentration: 0.1%). Following incubation of the cells for 24 hours with substances, 50 μl of the supernatant was discarded and then 50 μl of Luciferase Constant-Light Reagent (Roche Molecular Biochemicals) was added to lyse the cells and initiate the luciferase reaction. Luminescence, as a measure of luciferase activity, was detected in a Packard TopCount. Transcriptional activation in the presence of a test substance was expressed as fold-change in luminescence compared to that of cells incubated in the absence of the substance. EC50 values were calculated using the XLfit program (ID Business Solutions Ltd. UK).
The compounds according to formula (I) have an activity in at least one of the above assays (EC50 or IC50) of 1 nM to 100 μM, preferably 1 nM to 10 μM, more preferably 1 nM to 1 μM.
For example, the following compounds showed the following IC50 values in the binding assay:
LXRalpha Binding LXRbeta Binding
Example
IC50 [μmol/1] IC50 [μmol/1]
4 18.0 0.72
4.1 0.77
87 15.6 2.8 These results have been obtained by using the foregoing test.
The compounds of formula I and/or their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or suspensions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils. Oral administration is preferred.
The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula I and/or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers might, however, be required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi- synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency- improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.
The dosage of the compounds of formula I can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 to 2000 mg, especially about 1 to 500 mg, comes into consideration. Depending on severity of the disease and the precise pharmacokinetic profile the compound could be administered with one or several daily dosage units, e.g. in 1 to 3 dosage units.
The pharmaceutical preparations conveniently contain about 1-500 mg, preferably 1-200 mg, of a compound of formula I.
The following examples serve to illustrate the present invention in more detail. They are, however, not intended to limit its scope in any manner.
Examples
Abbreviations:
BOC = t-butyloxycarbonyl, DEAD= diethyl azodicarboxylate, DMF = dimethylformamide, HBTU =2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl-uronium hexafluoro phosphate, TBME = terf-butyl-methyl ether, THF = tetrahydrofuran, TFA = trifluoroacetic acid.
Ligands:
MeOBIPHEP1' (6,6'-Dimethoxy[l,l'-biphenyl]-2,2'-diyl)bis[bis(3,5- di-ter£-butyl-4-methoxyphenyl)phosphine)
2-Furyl-MeOBIPHEP1' (6,6'-Dimethoxybiphenyl-2,2'-diyl)bis(di-2- furylphosphine)
BITIANP2) 3,3'-bis-diphenylphosphanyl- IH, 1 'H- [4,4'] - biisothiochromenyl
3,5-XyM-MeO-MeOBIPHEP1' (6,6'-Dimethoxy[l,l'-biphenyl]-2,2'-diyl)bis[bis(3,5- di-ter£-butyl-4-methoxyphenyl)phosphine)
1) Ligands are known in the art and/or can be prepared according to the examples or methods as described in EP O 398 132, WO 92/16535, EP O 104 375 or EP 0 580 331.
2) Benincori, T.; Brenna, E.; Sannicolo, F.; Trimarco, L.; Antognazza, P.; Cesarotti, E.; Demartin, F.; Pilati, T. /. Org. Chem. 1996, 61, 6244.
Example 1
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(3-methoxy- benzenesulfonyl)-piperazin-2-yl]-methanone
Step 1: 4-(4-fluoro-2-methyl-phenyl)-piperazine-l,3-dicarboxylic acid 1-terf-butyl ester (CAS Reg. No.: [499780-10-8]) (100 mg) in DMF (2.5 mL) was treated with l-(2,5- dimethylphenyl)piperazine (62 mg), 2-(benzotriazol-l-yl)-N,N,N',N'-tetramethyl- uronium hexafluoro phosphate (HBTU) (123 mg) and triethylamine (124 μL) at ambient temperature for 5h. Water was added, the phases were separated and the inorganic phase was extracted with ferf-butyl-methyl ether (TBME). The combined organic phases were washed with water and brine, dried (Na2SO/t), filtered and evaporated. Purification by chromatography (Siθ2, π-heptane/ethyl acetate 2:1) gave 3-[4-(2,5-dimethyl-phenyl)- piperazine- 1 -carbonyl] -4- (4-fluoro-2-methyl-phenyl) -piperazine- 1 -carboxylic acid tert- butyl ester as a white solid (143 mg), MS: 511.5 ( [M+H]+).
Step 2: To a solution of 3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- 2-methyl-phenyl) -piperazine- 1 -carboxylic acid tert-butγ\ ester (133 mg) in ethanol (5 mL) was added a saturated solution of hydrogen chloride in ethanol (1 mL). The mixture was stirred at room temperature for 2h, and was concentrated to give [4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] - [ 1 - (4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -methanone hydrochloride as crude white solid, MS : 411.5 ([M+H]+). Step 3: To a solution of [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl- phenyl) -piperazin-2-yl] -methanone hydrochloride (42 mg) in DMF (1 mL) was added 3- methoxybenzene sulfonyl chloride (21.4 mg) and triethyl amine (40 μL). The reaction mixture was stirred at ambient temperature for 2h, was diluted with ethyl acetate and washed with a saturated aqueous solution of NaHCO3. The combined organic phases were washed with water and brine, dried (Na2SO4), filtered and evaporated. The crude product was purified by column chromatography (Siθ2, π-heptane/ ethyl acetate 2:1) to give [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(3- methoxy-benzenesulfonyl) -piperazin-2-yl] -methanone (42 mg) as white solid, MS : 581.3 ( [M+H]+).
Example 2
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1-yl] -methanone
Step 1: To a solution of benzylamine (60.3 mL) and triethylamine (96.3 mL) in THF (800 mL) was added chloroacetyl chloride (45.8 mL) at 0 0C. The reaction mixture was allowed to warm to room temperature over night. Additional chloroacetyl chloride (4.6 mL) was added and stirring was continued until no starting material could be detected. The reaction mixture was filtered, washed with ethyl acetate and concentrated. The crude product was crystallized from dichloromethane to yield N-benzyl-2-chloro-acetamide (71.6 g) as off- white solid.
Step 2: To a solution of N-benzyl-2-chloro-acetamide (20 g) in DMF (200 mL) were added 4-fluoro-2-methylaniline (13.3 mL) and N,N-diisopropylethylamine (22.2 mL). The reaction mixture was heated to 1000C over night, cooled to room temperature, and the mixture was diluted with ethyl acetate and washed with water. The combined inorganic phases were extracted with ethyl acetate and the combined organic phases were dried (Na2SO4), filtered and evaporated. The crude product was purified by chromatography (Siθ2, π-heptane/ethyl acetate 1:2) to give N-benzyl-2-(4-fluoro-2- methyl-phenylamino)-acetamide (20 g) as grey solid, MS: 273.0 ([M+H]+).
Step 3: To a solution of N-benzyl-2-(4-fluoro-2-methyl-phenylamino)-acetamide (17 g) in THF (500 mL) was added a solution of borane tetrahydrofuran complex (499.4 mL, IM in THF). The solution was heated to reflux for 4h, was concentrated and redissolved in a mixture of 2M HCl and TBME. The inorganic phase was extracted with TBME, the organic phases washed with 2M HCl. The pH of the combined inorganic phases was adjusted to pH 11 by the addition of concentrated NaOH, and the solution was extracted with TBME. The combined organic phases were dried (Na2SO4), filtered and evaporated to yield N-benzyl-N'-(4-fluoro-2-methyl-phenyl)-ethane-l,2-diamine (15.1 g) as a crude product, MS: 259.3 ([M+H]+).
Step 4: To N-benzyl-N'-(4-fluoro-2-methyl-phenyl)-ethane-l,2-diamine (15.1 g) in toluene (150 mL) was added N,N-diisopropylethylamine (33.8 mL) and 2,3- dibromopropionic acid ethyl ester (25.61 mL) in toluene (350 mL). The reaction mixture was heated to 135°C for 18 h, cooled to room temperature, and the precipitated solid was removed by filtration. The solution was concentrated, and the crude material was redissolved in TBME and washed with an aqueous 2M solution of Na2CO3 and brine, dried (Na2SO4), filtered and evaporated. Chromatography (SiC>2, π-heptane/ethyl acetate 97:3) gave 4-benzyl-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester (5.5 g) as yellow oil, MS: 357.3 ([M+H]+) and l-benzyl-4-(4-fluoro-2-methyl- phenyl)-piperazine-2-carboxylic acid ethyl ester (3.3 g) as yellow oil, MS: 357.1 ( [M+H]+).
Step 5: 4-Benzyl-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester (1 g) in ethyl acetate (10 mL) was hydrogenated in the presence of 10% Pd/C (149 mg) and acetic acid (1 mL). After removal of the catalyst and evaporation of the solvent, the residue was dissolved in DMF (8 mL) and was treated with 3-chlorobenzenesulfonyl chloride (280 μL) and triethylamine (1.96 mL) at ambient temperature until no starting material could be detected by TLC. The mixture was diluted with ethyl acetate and washed with an aqueous solution of NaHCC>3, dried (Na2SC>4), filtered and evaporated. Purification by chromatography (SiC>2, π-heptane/ethyl acetate 2:1) yielded 4-(3-chloro- benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester as a white solid (750 mg), MS: 441.3 ( [M+H, ICl]+). Step 6: To a solution of 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester (730 mg) in tetrahydrofuran (20 mL) was added 1 M aqueous LiOH solution (16.6 mL) and methanol until a clear solution was obtained. The mixture was stirred at reflux for Ih, IM KHSO4 (20 mL) was added and the inorganic phase was extracted with ethyl acetate. The combined organic phases were dried (Na2SO4), filtered and evaporated to yield 4-(3-chloro-benzenesulfonyl)-l-(4- fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid as a light yellow solid, MS: 411.0 ( [M-H1 ICl]-).
Step 7: In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid, l-(2,5-dimethylphenyl)-piperazine, HBTU and triethylamine in DMF was prepared [4-(3-chloro-benzenesulfonyl)-l-(4- fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- methanone as a white solid, MS: 584.7 ( [M+H, ICl]+).
Example 3
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(5- chloro-2-methyl-phenyl)-piperazin- 1-yl] -methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 604.8 ( [M+H, ICl]+).
Example 4
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl)-piperazin- 1-yl] -methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydro-chloride was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 624.5 ( [M+H, ICl]+).
Example 5 (-)-[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4- (2,5-dichloro-phenyl)-piperazin-l-yl]-methanone
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone (example 4) was separated into the enantiomers by chiral HPLC on Chiralpak AD using π-heptane / 30 % ethanol as the mobile phase to give (+)-[4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)- piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as an off-white solid, MS: 624.5 ([M+H, ICl]+) and (-)-[4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as an off-white solid, MS: 624.5 ( [M+H, ICl]+).
Example 6
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-(4-o-tolyl- piperazin-l-yl)-methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid and l-(2-methylphenyl)piperazine was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- (4-o-tolyl-piperazin-l-yl)-methanone as a light yellow foam, MS: 571.2 ( [M+H, ICl]+).
Example 7
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl]-methanone
Steps 1-4: In analogy to example 2, steps 1-4, from benzylamine, chloroacetyl chloride, aniline and 2,3-dibromopropionic acid ethyl ester was prepared 4-benzyl-l -phenyl - piperazine-2-carboxylic acid ethyl ester as a light yellow oil, MS: 325.5 ([M+H]+).
Step 5: In analogy to example 2, step 5, from 4-benzyl-l-phenyl-piperazine-2-carboxylic acid ethyl ester and 3-methoxy-benzenesulfonyl chloride was prepared 4-(3-methoxy- benzenesulfonyl)-l-phenyl-piperazine-2-carboxylic acid ethyl ester as a light yellow oil,
MS: 405.3 ([M+H]+).
Step 6: In analogy to example 2, step 6, from 4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazine-2-carboxylic acid ethyl ester was prepared 4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazine-2-carboxylic acid as an off white solid, MS: 375.5 ([M+H]+). Step 7: In analogy to example 1, step 1, from 4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)piperazine dihydrochloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl]-methanone as a white solid, MS: 589.0 ( [M+ H, ICl]+).
Example 8
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone
In analogy to example 1, step 1, from 4- (3-methoxy-benzenesulfonyl)-l -phenyl - piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared [4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] - [4-(3-methoxy-benzenesulfonyl) - 1 -phenyl-piperazin- 2-yl] -methanone as a white solid, MS: 548.8 ( [M+H]+).
Example 9
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl] -methanone In analogy to example 1, step 1, from 4- (3-methoxy-benzenesulfonyl)-l -phenyl - piperazine-2-carboxylic acid and l-(5-chloro-2-methylphenyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl] -methanone as a white solid, MS: 568.8 ( [M+ H, ICl]+).
Example 10 [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)- piperazin- 1-yl] -methanone
Steps 1-4: In analogy to example 2, steps 1-4, from benzylamine, chloroacetyl chloride, o- toluidine and 2,3-dibromopropionic acid ethyl ester was prepared 4-benzyl-l-o-tolyl- piperazine-2-carboxylic acid ethyl ester as an orange oil, MS: 339.4 ([M+H]+).
Step 5: In analogy to example 2, step 5, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester and 3-chlorobenzenesulfonyl chloride was prepared 4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 422.9 ([M+H, ICl]+). Step 6: In analogy to example 2, step 6, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl- piperazine-2-carboxylic acid ethyl ester was prepared 4-(3-chloro-benzenesulfonyl)-l-o- tolyl-piperazine-2-carboxylic acid as a light yellow solid, MS: 393.3 ( [M-H, ICl]").
Step 7: In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl- piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydrochloride was prepared [4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro- phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 606.6 ([M+H, ICl]+).
Example 11
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1- yl] -methanone as a light yellow solid, MS: 586.8 ( [M+H, ICl]+).
Example 12
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(3-chloro- benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] - methanone as a light yellow solid, MS: 567.3 ([M+H, ICl]+).
Example 13
[l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
Step 1: Under argon at 00C, to a solution of ethyl l,4-dibenzylpiperazine-2-carboxylate (10 g) in dichloroethane (40 mL) a solution of 1-chloroethyl chloroformate (4.73 mL) in dichloroethane (14 mL) was added dropwise over a period of 10 min. The reaction mixture was stirred for 15 minutes at 00C, and then heated to reflux overnight. The solvent was evaporated and the crude material was dissolved in ethanol and heated at reflux overnight. The solvent was evaporated and the residue was dissolved in water and extracted with diethyl ether (x2) and CH2CI2 (x2). A saturated solution of NaHCU3 was then added to the water phase, and the inorganic phase was extracted with CH2CI2 (x2). The organic layers were then combined, washed with brine, dried (Na2SO4), filtered and concentrated to give l-benzyl-piperazine-2-carboxylic acid ethyl ester as crude product,
MS: 248.9 ([M+H]+).
Step 2: A solution of l-benzyl-piperazine-2-carboxylic acid ethyl ester (300 mg) in DMF (13 mL) was treated with triethylamine (0.5 mL) and 3-methoxybenzene sulfonyl chloride (274.6 mg) at RT for 2 hours. Water was added, and the inorganic layer was extracted with ethyl acetate (x3). The combined organic layers were dried (Na2SO4), filtered and evaporated to yield l-benzyl-4-(3-methoxy-benzenesulfonyl)-piperazine-2- carboxylic acid ethyl ester as a colorless oil (417 mg ), MS: 419.3 ( [M+H]+).
Step 3: In analogy to example 2, step 6, from l-benzyl-4-(3-methoxy-benzenesulfonyl)- piperazine-2-carboxylic acid ethyl ester was prepared l-benzyl-4-(3-methoxy- benzenesulfonyl)-piperazine-2-carboxylic acid, which was subjected to the next reaction without further purification. MS: 389.5 ( [M-H]").
Step 4: In analogy to example 1, step 1, from l-benzyl-4-(3-methoxy-benzenesulfonyl)- piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared [1- benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 563.5 ([M+H]+).
Example 14 (-)-[l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone was separated into the enantiomers by chiral HPLC on Chiralpak AD using π-heptane / 25 % isopropanol as the mobile phase to give (+)-[l- benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone as a colorless oil, MS: 563.3 ( [M+H]+ and (-)-[l-benzyl-4-(3- methoxy-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- methanone as a colorless oil, MS: 563.3 ([M+H]+).
Example 15 [l-Benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone Step 1: In analogy to example 1, step 1, from l,4-dibenzylpiperazine-2-carboxylic acid (CAS Reg. No.: [215597-67-4]) and l-(2,5-dimethylphenyl)piperazine was prepared (1,4- dibenzyl-piperazin-2-yl)-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 483.3 ([M+H]+).
Step 2: In analogy to example 13, steps 1-2, from (l,4-dibenzyl-piperazin-2-yl)-[4-(2,5- dimethyl-phenyl)-piperazin-l-yl]-methanone and 3-chlorobenzene sulfonyl chloride was prepared [ l-benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 567.3 ([M+H, ICl]+).
Example 16 [l-Benzyl-4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone
In analogy to example 13 steps 1-2, from (l,4-dibenzyl-piperazin-2-yl)-[4-(2,5-dimethyl- phenyl) -piperazin- 1-yl] -methanone and 3,5-dimethylisoxazole-4- sulfonyl chloride was prepared [l-benzyl-4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1-yl] -methanone as a white foam, MS: 552.3 ([M+H]+).
Example 17
[4-(3-Chloro-benzenesulfonyl)-l-propyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
Step 1: To a solution of N-l-Boc-2-piperazinecarboxylic acid methyl ester (CAS Reg. No: [129799-15-1]) (1 g) in DMF (5 mL) was added 3-chlorobenzenesulfonyl chloride (0.95 g) and triethylamine (1.71 mL). The reaction mixture was stirred at RT overnight. Water was added and the mixture was extracted with ethyl acetate (x2). The combined organic layers were washed with water (x2) and brine, were dried (Na2SC>4), filtered and evaporated. Purification by chromatography (SiCh, π-heptane/ ethyl acetate 3:1) yielded 4-(3-chloro-benzenesulfonyl)-piperazine-l,2-dicarboxylic acid l-tert-buty\ ester 2- methyl ester as white foam (1.66 g), MS: 436.3 ( [M+NH4, ICl]+).
Step 2: In analogy to example 2, step 6 (ambient temperature), from 4-(3-chloro- benzenesulfonyl)-piperazine-l,2-dicarboxylic acid 1-terf-butyl ester 2-methyl ester was prepared 4-(3-chloro-benzenesulfonyl)-piperazine-l,2-dicarboxylic acid l-tert-buty\ ester as a white foam, MS: 403.2 ( [M-H, ICl]"). Step 3: In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-piperazine- 1,2-dicarboxylic acid 1-terf-butyl ester and l-(2,5-dimethylphenyl)-piperazine was prepared 4-(3-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)-piperazine-l- carbonyl]-piperazine-l-carboxylic acid tert-butγ\ ester as a white foam, MS: 577.4 ( [M+H, ICl]+).
Step 4: To a solution of 4-(3-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-piperazine-l-carboxylic acid tert-butyl ester (2.18 g) in ethanol (21.8 mL) was added a saturated solution of HCl in ethanol (21.8 mL) at 00C. The reaction mixture was stirred at ambient temperature overnight, the solution was concentrated and the residue dissolved in a mixture of NaHCU3 solution and ethyl acetate. The inorganic phase was extracted with ethyl acetate (x3) and the combined organic layers were washed with brine, dried (Na2SO4), filtered and evaporated to yield [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l- yl]-methanone as crude product (1.79 g), MS: 477.0 ([M+H, ICl]+). Step 5: To a solution of [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone (100 mg) in acetone (4 mL) was added cesium carbonate (82 mg), followed by 1-bromopropane (21 μL). The reaction mixture was stirred at reflux overnight. Water was added and the reaction mixture was extracted with ethyl acetate (x2). The combined organic layers were washed with brine, dried (Na2SC>4), filtered and evaporated. Purification by chromatography (SiO2, π-heptane/ethyl acetate 3:1) yielded [4-(3-chloro-benzenesulfonyl)-l-propyl-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone as a white foam (75 mg), MS: 519.3 ([M+H, ICl]+).
Example 18
[l-Butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone
In analogy to example 17, step 5, from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone and 1 -bromobutane was prepared [1- butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin- l-yl]-methanone as a white foam, MS: 533.4 ( [M+H, ICl]+).
Example 19
[4-(3-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone In analogy to example 17, step 5, from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone and 1-bromopentane was prepared [4-(3-chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 547.3 ([M+H, ICl]+).
Example 20
[4-(3-Chloro-benzenesulfonyl)-l-isobutyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
In analogy to example 17, step 5, from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin- 1-yl] -methanone and l-bromo-2-methylpropane was prepared [4-(3-chloro-benzenesulfonyl)-l-isobutyl-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin- 1-yl] -methanone as a white foam, MS: 533.2 ([M+H, ICl]+).
Example 21
[4-(3-Chloro-benzenesulfonyl)-l-phenethyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
In analogy to example 17, step 5, from [4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl)-piperazin- 1-yl] -methanone and (2-bromoethyl) -benzene was prepared [4-(3-chloro-benzenesulfonyl)-l-phenethyl-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin- 1-yl] -methanone as a colorless oil, MS: 581.3 ( [M+H, ICl]+).
Example 22 [4-(4-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
Steps 1-3: In analogy to example 17, steps 1-3, from N-l-Boc-2-piperazinecarboxylic acid methyl ester (CAS Reg. No: [129799-15-1]), 4-chlorobenzenesulfonyl chloride and 1- (2,5-dimethylphenyl)-piperazine was prepared 4-(4-chloro-benzenesulfonyl)-2-[4-(2,5- dimethyl-pheny^-piperazine-l-carbonylj-piperazine-l-carboxylic acid tert-butγ\ ester as a light yellow foam, MS: 577.4 ( [M+H, ICl]+).
Step 4: To a solution of 4-(4-chloro-benzenesulfonyl)-2-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-piperazine-l-carboxylic acid tert-butγ\ ester (1.64 g) in ethanol
(16.4 mL) was added a saturated solution of HCl in ethanol (16.4 mL) at 00C. The reaction mixture was stirred at ambient temperature for 2 h and concentrated to give [4- (4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- methanone hydrochloride, MS: 477.0 ( [M+H, ICl]+).
Step 5: To a solution of [4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone hydrochloride (100 mg) in acetone (4 mL) was added cesium carbonate (254 mg), followed by 1-bromopentane (27 μL). The reaction mixture was stirred at ambient temperature for 1 h. Additional cesium carbonate (127 mg) and 1-bromopentane (14 μL) were added and stirring was continued at reflux over night. Water was added and the reaction mixture was extracted with ethyl acetate (x2). The combined organic layers were washed with brine, dried (Na2SO4), filtered and evaporated. Purification by chromatography (Siθ2, π-heptane/ ethyl acetate 3:1) yielded [4-(4-chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 547.3 ([M+H, ICl]+).
Example 23
[l-Butyl-4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-l-yl]-methanone
In analogy to example 20, step 5, from [4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4- (2,5-dimethyl-phenyl) -piperazin-l-yl]-methanone hydrochloride and 1 -bromobutane was prepared [ l-butyl-4-(4-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 533.3 ([M+H, ICl]+).
Example 24
[4-(4-Chloro-benzenesulfonyl)-l-phenyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1-yl] -methanone
Under argon an oven-dried flask was charged with tris(dibenzylideneacetone)dipalladium (9.6 mg), sodium tert butylate (40 mg) and 2(di- ter£-butylphosphino)biphenyl (6.3 mg). Then [4- (4-chloro-benzenesulfonyl) -piperazin - 2-yl]-[4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] -methanone (100 mg), previously prepared from [4-(4-chloro-benzenesulfonyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl) - piperazin- 1-yl] -methanone hydrochloride by extraction under basic conditions, in toluene (5 mL) was added, followed by a solution of bromobenzene (55 μL) in toluene (3 mL). The reaction mixture was stirred at 800C overnight. The mixture was cooled to room temperature, an aqueous solution of NaHCC>3 was added, the phases were separated, and the inorganic one was extracted with ethyl acetate (x3). The combined organic layers were dried (Na2SC>4), filtered and evaporated. Purification by chromatography (Siθ2, π-heptane/ethyl acetate 3:1; ISOLUTE Flash NH2, n- heptane/ ethyl acetate) and trituration with π-heptane gave [4-(4-chloro- benzenesulfonyl) - 1 -phenyl-piperazin-2-yl] - [4- (2,5-dimethyl-phenyl) -piperazin- 1-yl] - methanone as a white solid, MS: 553.3 ( [M+H, ICl]+).
Example 25
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl) -piperazin- 1-yl] -methanone
Step 1: In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 2-chlorobenzenesulfonyl chloride was prepared 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-2- carboxylic acid ethyl ester as a yellow oil, MS: 441.1 ([M+H, ICl]+).
Step 2: In analogy to example 2, step 6, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid ethyl ester was prepared 4-(2-chloro- benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-2-carboxylic acid as a white solid, MS: 410.9 ( [M-H, ICl]").
Step 3: In analogy to example 1, step 1, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro- 2-methyl-phenyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydrochloride was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 626.8 ( [M+H, ICl]+).
Example 26
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone
In analogy to example 1, step 1, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid (example 25, step 2) and l-(5-chloro-orf/jo- tolyl)-piperazine, was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl- phenyl)-piperazin-2-yl] - [4- (5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone as a white solid, MS: 604.8 ( [M+H, ICl]+).
Example 27
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1-yl] -methanone In analogy to example 1, step 1, from 4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazine-2-carboxylic acid (example 25, step 2) and l-(2,5- dimethylphenyl)-piperazine was prepared [4-(2-chloro-benzenesulfonyl)-l-(4-fluoro-2- methyl-phenyl)-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 584.8 ( [M+H, ICl]+).
Example 28
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene- l-sulfonyl)-piperazin-2-yl] -methanone
Step 1: In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 1-naphthalenesulfonyl chloride was prepared l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- l-sulfonyl)-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 457.3 ([M+H]+).
Step 2: In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene-1-sulfonyl) -piperazine-2-carboxylic acid ethyl ester was prepared l-(4- fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazine-2-carboxylic acid as a white solid, MS: 427.0 ( [M-H]").
Step 3: In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene-1-sulfonyl) -piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)- piperazine dihydrochloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[l-(4- fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 641.2 ( [M+H, ICl]+).
Example 29
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene- l-sulfonyl)-piperazin-2-yl] -methanone
In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)- 4- (naphthalene- l-sulfonyl)-piperazin-2-yl] -methanone as a white solid, MS: 621.0
( [M+H, ICl]+).
Example 30 [4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene- l-sulfonyl)-piperazin-2-yl] -methanone
In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(naphthalene-l-sulfonyl)-piperazin-2-yl] -methanone as a white solid, MS: 601.0
( [M+H]+).
Example 31
[l-(4-Fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazin-2-yl]-[4-(3- trifluoromethyl-pyridin-2-yl)-piperazin- 1-yl] -methanone
In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl) -4- (naphthalene- 1- sulfonyl)-piperazine-2-carboxylic acid and l-(3-trifluoromethyl-pyridin-2-yl)-piperazine (CAS Reg. No.: [87394-63-6]) was prepared [l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene-l-sulfonyl)-piperazin-2-yl]-[4-(3-trifluoromethyl-pyridin-2-yl)-piperazin- 1-yl] -methanone as a white solid, MS: 642.3 ( [M+H]+).
Example 32
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl)-piperazin-2-yl] -methanone
Step 1: In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and 8-quinolinesulfonyl chloride was prepared 1- (4-fluoro-2-methyl-phenyl)-4-(quinoline-8-sulfonyl)-piperazine-2-carboxylic acid ethyl ester as a white solid, MS: 458.3 ( [M+H]+).
Step 2: In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl) -piperazine-2-carboxylic acid ethyl ester was prepared l-(4-fluoro-2-methyl- phenyl)-4-(quinoline-8-sulfonyl)-piperazine-2-carboxylic acid as a white solid, MS: 428.4 ( [M-H]").
Step 3: In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)-piperazine dihydro- chloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl- phenyl)-4-(quinoline-8-sulfonyl)-piperazin-2-yl] -methanone as a white solid, MS: 642.0 ( [M+H1 ICl]+). Example 33
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (quinoline-8-sulfonyl)-piperazin-2-yl]-methanone
In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-8- sulfonyl)-piperazine-2-carboxylic acid and l-(5-chloro-orf/jo-tolyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)- 4-(quinoline-8-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 621.8 ([M+H, ICl]+).
Example 34
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl)-piperazin-2-yl]-methanone
In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-8- sulfonyl)-piperazine-2-carboxylic acid and l-(2,5-dimethylphenyl)-piperazine was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (quinoline-8-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 602.0 ([M+H]+).
Example 35
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[4-(propane-2-sulfonyl)-l-o-tolyl-piperazin- 2-yl]-methanone
Step 1: In analogy to example 2, step 6, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid ethyl ester (example 10, steps 1-4) was prepared 4-benzyl-l-o-tolyl-piperazine-2- carboxylic acid as a white solid, MS: 309.3 ([M-H]").
Step 2: In analogy to example 1, step 1, from 4-benzyl-l-o-tolyl-piperazine-2-carboxylic acid and l-(2,5-dichlorophenyl)piperazine dihydrochloride was prepared (4-benzyl-l-o- tolyl-piperazin-2-yl)-[4-(2,5-dichloro-phenyl)-piperazin-l-yl]-methanone as a white solid, MS: 522.8 ( [M+H, ICl]+).
Step 3: In analogy to example 2, step 5 from (4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and iso-propylsulfonyl chloride was prepared [4-(2,5-dichloro-phenyl)-piperazin-l-yl]-[4-(propane-2-sulfonyl)-l-o-tolyl- piperazin-2-yl] -methanone as a white foam, MS: 539.3 ([M+H, ICl]+).
Example 36 [4-(Biphenyl-4-sulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin- l-yl]-methanone
In analogy to example 35, step 3, from (4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and 4-biphenylsulfonyl chloride was prepared [4-(biphenyl-4-sulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 649.3 ([M+H, ICl]+).
Example 37
3-{3-[4-(2,5-Dichloro-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperazine-l-sulfonyl}- thiophene-2-carboxylic acid methyl ester
In analogy to example 35, step 3, from 4-benzyl-l-o-tolyl-piperazin-2-yl)-[4-(2,5- dichloro-phenyl)-piperazin-l-yl]-methanone and 2-(methoxycarbonyl)thiophene-3- sulfonyl chloride was prepared 3-{3-[4-(2,5-dichloro-phenyl)-piperazine-l-carbonyl]-4- o-tolyl-piperazine-l-sulfonyl}-thiophene-2-carboxylic acid methyl ester as a white foam,
MS: 637.0 ([M+H]+).
Example 38
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-(3',6'- dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-methanone
Step 1: In analogy to example 1, step 1 , from 4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-
2-methyl-phenyl)-piperazine-2-carboxylic acid (example 2, step 5) and N-Boc piperazine was prepared 4-[4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazine-
2-carbonyl] -piperazine- 1-carboxylic acid tert-butγ\ ester as a white solid, MS: 580.8
( [M+H, ICl]+).
Step 2: In analogy to example 17, step 4, from 4-[4-(3-chloro-benzenesulfonyl)-l-(4- fluoro-2-methyl-phenyl) -piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-butγ\ ester was prepared [4-(3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)- piperazin-2-yl]-piperazin-l-yl-methanone as a white solid, MS: 481.0 ( [M+H, ICl]+).
Step 3: [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]- piperazin-1-yl-methanone (60 mg), 3-chloro-2,5-dimethylpyrazine (18.1 μL) and triethylamine (20.8 μL) in acetonitrile (1 mL) were heated to 1700C in the microwave. Water was added and the reaction mixture was extracted with ethyl acetate. The combined organic phases were washed with brine, dried (Na2SC>4), filtered and evaporated. Purification by chromatography (Siθ2, π-heptane/ethyl acetate 1:2) gave [4- (3-chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-(3',6'- dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-methanone as a yellow oil, MS: 587.3 ( [M+H, ICl]+).
Example 39
[l-Benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ l,2']bipyrazinyl-4-yl)-methanone
Step 1: In analogy to example 13, step 2, from l-benzyl-piperazine-2-carboxylic acid ethyl ester and 3-chlorobenzenesulfonyl chloride was prepared l-benzyl-4-(3-chloro- benzenesulfonyl)-piperazine-2-carboxylic acid ethyl ester as a yellow oil, MS: 423.1 ( [M+H, ICl]+).
Step 2: In analogy to example 2, Step 6 , from l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carboxylic acid ethyl ester was prepared l-benzyl-4-(3-chloro- benzenesulfonyl)-piperazine-2-carboxylic acid as an off-white solid, MS: 593.0 ([M-H, ICl]").
Step 3: In analogy to example 1, step 1, from l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carboxylic acid and 1-Boc-piperazine was prepared 4-[l-benzyl-4-(3- chloro-benzenesulfonyl) -piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-butγ\ ester as a white foam, MS: 562.8 ( [M+H, ICl]+). Step 4: In analogy to example 38, step 2, from 4-[l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazine-2-carbonyl] -piperazine- 1 -carboxylic acid tert-butγ\ ester was prepared [1- benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl]-piperazin-l-yl-methanone as a white foam, MS: 463 ([M+H, ICl]+).
Step 5: In analogy to example 38, step 3, from [l-benzyl-4-(3-chloro-benzenesulfonyl)- piperazin-2-yl]-piperazin-l-yl-methanone and 3-chloro-2,5-dimethylpyrazine was prepared [ l-benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] -(3',6'-dimethyl-
2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-methanone as a yellow oil, MS: 569.3 ([M+H, ICl]+).
Example 40 [4-(3-Chloro-phenyl)-piperidin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(propane-2- sulfonyl)-piperazin-2-yl]-methanone Step 1: In analogy to example 2, step 5, from 4-benzyl-l-(4-fluoro-2-methyl-phenyl)- piperazine-2-carboxylic acid ethyl ester and iso-propylsulfonyl chloride was prepared 1- (4-fluoro-2-methyl-phenyl)-4-(propane-2-sulfonyl)-piperazine-2-carboxylic acid ester as a colorless oil, MS: 373.1 ( [M+H, ICl]+).
Step 2: In analogy to example 2, step 6, from l-(4-fluoro-2-methyl-phenyl)-4-(propane- 2-sulfonyl)-piperazine-2-carboxylic acid ester was prepared l-(4-fluoro-2-methyl- phenyl)-4-(propane-2-sulfonyl)-piperazine-2-carboxylic acid as a yellow solid, MS: 343.1 ( [M-H1 ICl]-).
Step 3: In analogy to example 1, step 1, from l-(4-fluoro-2-methyl-phenyl)-4-(propane- 2-sulfonyl)-piperazine-2-carboxylic acid and 4-(3-chlorophenyl)-piperidine was prepared [4- (3-chloro-phenyl) -piperidin- 1 -yl] - [ 1 - (4-fluoro-2-methyl-phenyl) -A-
(propane-2-sulfonyl)-piperazin-2-yl]-methanone as a white solid, MS: 522.2 ( [M+H, ICl]+).
Example 41
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ l,2']bipyrazinyl-4-yl)-methanone
In analogy to example 1, step 1, from 4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazine- 2-carboxylic acid and 3',6'-dimethyl-3,4,5,6-tetrahydro-2H-[l,2']bipyrazinyl (CAS Reg. No.: [59215-42-8]) was prepared [4-(3-chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2- yl]-(3',6'-dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl)-methanone as a white solid, MS: 569.3 ([M+H, ICl]+).
Example 42
Cis-[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl]-methanone
Step 1: Cis-4-phenylnipecotic acid hydrochloride (CAS Reg. No. [858430-42-9]) (195 mg) (three times suspended in toluene and evaporated under reduced pressure to remove water) was suspended in hexamethyldisilazane (4 mL) and refluxed for 3 h. The solution was evaporated under reduced pressure and dissolved in THF (4 mL). 3-Methoxybenzene sulfonyl chloride (0.13 mL) was added and the solution was stirred for 16 h at ambient temperature. H2O was added and after Ih the solvents were evaporated. The residue was partitioned between water/ ethyl acetate (3x), the organic phases were washed with brine, dried (Na2SOzO, filtered and evaporated. Purification by chromatography (SiO2, n- heptane/ethyl acetate 1:1) gave cis-l-(3-methoxy-benzenesulfonyl)-4-phenyl-piperidine- 3-carboxylic acid as a white solid, MS: 374.3 (M-H])".
Step 2: In analogy to example 1, step 1, from cis-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidine-3-carboxylic acid and l-(2,5-dimethylphenyl)piperazine was prepared cis-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl]-methanone as a white solid (mp 192°C), MS: 548.4 ([M+H])+.
Example 43
[4-(2,5-Dimethyl-phenyl)-piperazm-l-yl]-[(3S,4S)-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl]-methanone Cis-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[-l-(3-methoxy-benzenesulfonyl)-4- phenyl-piperidin-3-yl]-methanone was separated into the enantiomers by chiral HPLC on Chiralpak AD using π-heptane / 25 % isopropanol as the mobile phase to give [4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] - [ (3S,4S) - 1 - (3-methoxy-benzenesulfonyl) -4-phenyl- piperidin-3-yl]-methanone as a white foam, MS: 548.3 ( [M+H])+ and [4-(2,5-dimethyl- phenyl) -piperazin- l-yl]-[(3R,4R) -1 -(3-methoxy-benzenesulfonyl) -4-phenyl-piperidin-3- yl]-methanone as white foam, MS: 548.3 ( [M+H])+.
Example 44
[Trans- l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidm-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone
Step 1: In analogy to example 1, step 1, from trans-N-Boc-4-phenyl-nipecotic acid (CAS Reg. No.: [170838-49-0]) and l-(2,5-dimethylphenyl)piperazine was prepared trans-3- [4- (2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tot-butyl ester as a white foam, MS: 478.2 ([M+H])+.
Step 2: In analogy to example 22, step 4, from trans-3- [4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared trans- [4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] -(-4-phenyl-piperidin-3-yl)- methanone hydrochloride as a white foam, MS: 378.4 ([M+H])+.
Step 3: In analogy to example 1, step 3, from trans-[4-(2,5-dimethyl-phenyl)-piperazin-l- yl]-(-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [trans-l-(3-chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4- (2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 552.1 ( [M+H, ICl] )+.
Example 45
[Trans- l-(3,5-Dimethyl-isoxazole-4-sulfonyl)-4-phenyl-piperidin-3-yl] -[4-(2,5- dimethyl-phenyl)-piperazin- 1-yl] -methanone
In analogy to example 1, step 3, from trans-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-(- 4-phenyl-piperidin-3-yl) -methanone hydrochloride and and 3,5-dimethylisoxazole-4- sulfonyl chloride (CAS Reg. No.: [80466-79-1]) was prepared [trans- 1 -(3,5-dimethyl- isoxazole-4-sulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l- yl] -methanone as a white foam, MS: 537.4 ( [M+H] )+.
Example 46
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(3-methoxy-benzenesulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone
Step 1: To a solution of 2-methylphenylzinc chloride ( [84109-17-1], previously prepared from otolylmagnesium chloride (44.07 mL) and zinc chloride (8.81 g) in THF (200 mL)) a mixture of 4-trifluoromethanesulfonyloxy-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) (11.4 g) in THF (90 mL) followed by tetrakis(triphenylphosphine)palladium(0) (1.02 g) was added. The reaction mixture was stirred at room temperature over night and then was quenched with ice. The mixture was diluted with tert-butyl methyl ether and washed with 2 M aqueous sodium carbonate solution. The aqueous phases were extracted with tert-butyl methyl ether. The combined organic layers were washed with brine, dried (Na2SO4), filtered and evaporated. Purification by chromatography (SiO2, π-heptane/ ethyl acetate 5:1) gave A-o- tolyl-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester 3-methyl ester as light yellow oil, MS: 332.0 ( [M+H] )+.
Step 2: In analogy to example 2, step 6, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid 1 -tert-butyl ester 3-methyl ester was prepared 4-o-tolyl-5,6-dihydro- 2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester as a white solid, MS: 316.2 ( [M-H])".
Step 3: In a glove box an autoclave was charged with 4-o-tolyl-5,6-dihydro-2ff-pyridine- 1,3-dicarboxylic acid 1 -tert-butyl ester (2.5 g), [Ru(OAc)2 ( [R) -(2-furyl) -MeOBIPHEP)] (24 mg), triethylamine (1.1 mL) and methanol (25mL). The asymmetric hydrogenation was run for 60 h at 800C under 40 bar of hydrogen. After cooling to room temperature the pressure was released from the autoclave, the methanol solution was diluted with tert- butyl methyl ether (320 mL) and extracted with 1 M aqueous sodium hydroxide solution (2x, 320 mL). The aqueous layer was poured on ice, acidified with ice-cold 2 M aqueous hydrochloric acid solution to pH 1 and extracted with ethyl acetate (3x). The combined organic layers were dried (Na2SO4), filtered and concentrated in vacuo and triturated from π-heptane to give (3S,4S)-4-o-tolyl-piperidine-l,3-dicarboxylic acid 1-terf-butyl ester as a white solid, MS: 318.2.
Step 4: In analogy to example 1, step 1, from (3S,4S)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester and l-(2,5-dimethylphenyl)piperazine was prepared (3S,4S)-3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperidine-l- carboxylic acid tert-butγ\ ester as a white foam, MS: 492.3 ( [M+H] )+.
Step 5: In analogy to example 22, step 4, from (3S,4S)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-butγ\ ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-4-o-tolyl-piperidin-3-yl)- methanone hydrochloride as colorless oil, MS: 392.4 ([M+H])+.
Step 6: In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-methoxybenzene- sulfonyl chloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(3- methoxy-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl] -methanone as a white foam, MS: 562.5 ([M+H])+.
Example 47
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone
In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)- 4-o-tolyl-piperidin-3-yl) -methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]- [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 566.4 ( [M+H, ICl] )+.
Example 48 [4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o-tolyl- piperidin-3-yl)-methanone In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)- 4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o- tolyl-piperidin-3-yl)-methanone as a white foam, MS: 470.1 ([M+H])+.
Example 49
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone
Step 1: In analogy to example 1, step 1, from (3S,4S)-4-phenyl-piperidine-l,3- dicarboxylic acid l-tert-butγl ester (CAS Reg. No.: [197900-77-9]) and l-(2,5- dimethylphenyl)piperazine was prepared (3S,4S)-3-[4-(2,5-dimethyl-phenyl)-piperazine- l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester as a white foam, MS:
478.28 ([M+H])+.
Step 2: In analogy to example 22, step 4, from (3S,4S)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-phenyl-piperidin-3-yl)- methanone hydrochloride as crude product, MS: 392.4 ([M+H])+.
Step 3: In analogy to example 1, step 3, from [4- (2,5-dimethyl-phenyl) -piperazin- 1-yl] -
((3S,4S)-4-phenyl-piperidin-3-yl) -methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-phenyl- piperidin-3-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam,
MS: 552.2 ([M+H, 1C1])+.
Example 50
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-phenyl- piperidin-3-yl)-methanone In analogy to example 1, step 3, [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-4- phenyl-piperidin-3-yl) -methanone hydrochloride and methanesulfonyl chloride was prepared [4-(2,5-dimethyl-phenyl) -piperazin- 1-yl] -((3S,4S)-1 -methanesulfonyl-4- phenyl-piperidin-3-yl) -methanone as a white foam, MS: 456.3 ( [M+H])+.
Example 51 [(3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone Step 1: In analogy to example 1, step 1, from (3R,4R)-4-phenyl-piperidine-l,3- dicarboxylic acid 1 -tert-butyl ester (CAS Reg. No.: [197900-84-8]) and l-(2,5- dimethylphenyl)piperazine was prepared (3R,4R)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester as a white foam, MS:478.27 ( [M+H] )+.
Step 2: In analogy to example 22, step 4, from (3R,4R)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3R,4R)-4-phenyl-piperidin-3-yl)- methanone hydrochloride, which was directly subjected to the following reaction, MS: 378.4 ([M+H, 1C1])+.
Step 3: In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3R,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3R,4R)-l-(3-chloro-benzenesulfonyl)-4-phenyl- piperidin-3-yl]-[4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 552.2 ([M+H, 1C1])+.
Example 52
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(3-methoxy-benzenesulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone
Step 1: In analogy to example 46, step 3, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid l-tert-butγl ester using Ru(OAc)2( (S) -BITIANP as catalyst for the enantioselective hydrogenation was prepared (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid 1 -tert-butyl ester as a white solid, MS: 318.4 ([M-H])".
Step 2: To a solution of triphenylphosphine (2.66 g) in THF (30 ml) was added diethyl azodicarboxylate (1.58 mL) at 0 0C. After 30 minutes, methanol (1.58 mL) and a solution of (3R,4R)-4-o-tolyl-piperidine-l,3-dicarboxylic acid 1 -tert-butyl ester in THF (30 mL) were added subsequently at 0-5 0C. The reaction mixture was stirred for 3 h at room temperature. The reaction was quenched with a saturated aqueous solution of NH4Cl, tert-butyl methyl ether was added, and the phases were separated. The inorganic one was extracted with tert-butyl methyl ether (3 x 100ml). The combined organic layers were dried (Na2SO4), filtered and evaporated. Purification by chromatography (SiO2, CH2Cl2 to CH2Cl2/MeOH 95:5) yielded (3R,4R)-4-o-tolyl-piperidine-l,3-dicarboxylic acid 1 -tert- butyl ester 3-methyl ester as a colorless gum, MS: 334.1 ([M+H])+. Step 3: A mixture of (3R,4R)-4-o-tolyl-piperidine-l,3-dicarboxylic acid l-tert-buty\ ester 3-methyl ester (200 mg) and sodium methoxide (65 mg) in anhydrous toluene (6 mL) was heated at reflux over night. After cooling to room temperature the reaction mixture was quenched with water and concentrated in vacuo. The residue was dissolved in a mixture of 1,4-dioxane (3 mL) and 2 M aqueous sodium hydroxide solution (3 mL). After stirring at RT for 5 h the mixture was diluted with water and washed with two portions of tert-butγ\ methyl ether. The aqueous layer was cooled to 0 0C, acidified to pH 1-2 with ice-cold 1 M aqueous KHSO4 solution and extracted with ethyl acetate. The combined organic layers were dried (Na2SO4), filtered and evaporated to give (3S,4R)-4- o-tolyl-piperidine-l^-dicarboxylic acid 1-tert-butyl ester as a white solid, MS: 318.4 ([M- H])-.
Step 4: In analogy to example 1, step 1, from (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester and l-(2,5-dimethylphenyl)piperazine was prepared (3S,4R)-3-[4-(2,5-dimethyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperidine-l- carboxylic acid tert-butyl ester as a white solid, MS: 492.1 ( [M+H] )+.
Step 5: In analogy to example 22, step 4, from (3S,4R)-3-[4-(2,5-dimethyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l -carboxylic acid tert-butyl ester was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-o-tolyl-piperidin-3-yl)- methanone hydrochloride as a white solid, MS: 392.3 ([M+H])+. Step 6: In analogy to example 1, step 3, from [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-methoxybenzene- sulfonylchloride was prepared [4-(2,5-dimethyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(3- methoxy-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-methanone as a white solid, MS:
562.3 ([M+H]+.
Example 53
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl)-piperazin- 1-yl] -methanone
Step 1: In analogy to example 46, steps 1-2, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1 -tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 4-fluorophenylzinc bromide was prepared 4- (4-fluoro-phenyl) -
5, 6-dihydro-2ff- pyridine- 1,3-dicarboxylic acid 1 -tert-butyl ester as a white foam, MS:
320.5 ([M-H])". Step 2: In analogy to example 46, step 3, from 4-(4-fluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-butyl ester using [Ru(OAc)2( (R) -MeOBIPHEP)] as catalyst for the enantioselective hydrogenation was prepared (-)-(3S,4S)-4-(4-fluoro- phenyl)-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester as an off-white solid, MS: 322.5 ([M+H])+.
Step 3: In analogy to example 1, step 1, from (-)-(3S,4S)-4-(4-fluoro-phenyl)-piperidine- 1,3-dicarboxylic acid l-tert-butyl ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- phenyl)-piperidine-l-carboxylic acid tert-butyl ester as a white foam, MS: 516.3 ([M+H, ICl] )+.
Step 4: In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-(4-fluoro-phenyl)-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-(4-fluoro- phenyl)-piperidin-3-yl]-methanone hydrochloride as a white foam, MS: 416.4 ( [M+H, 1C1])+.
Step 5: In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3- chlorobenzenesulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] )+.
Example 54
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-(4-fluoro-phenyl)-l-(2- trifluoromethyl-benzenesulfonyl)-piperidin-3-yl] -methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(4-fluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- (trifluoromethyl)benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)- piperazin- 1 -yl] - [ (3S,4S) -4- (4-fluoro-phenyl) - 1 - (2-trifluoromethyl-benzenesulfonyl) - piperidin-3-yl] -methanone as a white foam, MS: 624.2 ([M+H, ICl] )+.
Example 55
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl)-piperazin- 1-yl] -methanone Step 1: In analogy to example 46, step 3, from 4-(4-fluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-butyl ester using [Ru(OAc)2((S)-(3,5-Xyl,4-MeO- MeOBIPHEP))] as catalyst for the enantioselective hydrogenation was prepared (3R,4R)- 4-(4-fluoro-phenyl)-piperidine-l,3-dicarboxylic acid l-tert-butyl ester as white foam, MS: 322.5 ([M-H])".
Step 2: In analogy to example 52, steps 2-3, from (3R,4R)-4-(4-fluoro-phenyl)- piperidine-l,3-dicarboxylic acid l-tert-buty\ ester was prepared (3S,4R)-4-(4-fluoro- phenyl)-piperidine-l,3-dicarboxylic acid l-tert-butyl ester as off-white foam, MS: 322.5 ( [M-H])-.
Step 3: In analogy to example 1, step 1, from (3S,4R)-4-(4-fluoro-phenyl)-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-(4-fluoro- phenyl)-piperidine-l-carboxylic acid tert-butyl ester as a light yellow foam, MS: 516.3
( [M+H, ICl] )+. Step 4: In analogy to example 22, step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-(4-fluoro-phenyl)-piperidine-l-carboxylic acid tert-butyl ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro- phenyl)-piperidin-3-yl]-methanone hydrochloride as a white foam, MS: 416.4 ( [M+H, ICl] )+. Step 5: In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3- chlorobenzenesulfonyl chloride was prepared [(3S,4R)-l-(3-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] )+.
Example 56
[(3S,4R)-l-(2-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl)-piperazin- 1-yl] -methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- chlorobenzenesulfonyl chloride was prepared [(3S,4R)-l-(2-chloro-benzenesulfonyl)-4- (4-fluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- methanone as a white foam, MS: 590.3 ( [M+H, ICl] )+. Example 57
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro-phenyl)-l- (pyridine-3-sulfonyl)-piperidin-3-yl]-methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-(4-fluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3- sulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)- 4-(4-fluoro-phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 557.1 ([M+H, 1C1])+.
Example 58 [(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone
Step 1: In analogy to example 46, step 1, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2-fluoro-4-methylphenylzinc bromide (CAS Reg. No. [737797- 14-7]) was prepared 4-(2-fluoro-4-methyl-phenyl)-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid 1-tert-butyl ester 3-methyl ester as light yellow oil, MS: 350.4 ( [M+H] )+.
Step 2: In analogy to example 46, step 2, 4-(2-fluoro-4-methyl-phenyl)-5,6-dihydro-2H- pyridine-l,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester was prepared 4-(2-fluoro- 4-methyl-phenyl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-tert-butyl ester as a white solid, MS: 334.2 (M-H])".
Step 3: In analogy to example 46, step 3 from 4-(2-fluoro-4-methyl-phenyl)-5,6-dihydro 2H-pyridine-l,3-dicarboxylic acid 1-tert-butyl ester using [Ru(OAc)2((R)-(2-furyl)- MeOBIPHEP)] as catalyst for the enantioselective hydrogenation was prepared (3S,4S) or (3R,4R)-4-(2-fluoro-4-methyl-phenyl)-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester as a white foam, MS: 336.2 (M-H])"; [α]D = - 62.82 (c= 0.962 g/100 mL, CHCl3).
Step 4: In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(2-fluoro-4-methyl- phenyl)-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl- phenyl) -piperazine- 1 -carbonyl] -4- (2-fluoro-4-methyl-phenyl) -piperidine- 1 -carboxylic acid tot-butyl ester as a white foam, MS: 530.3 ([M+H, ICl] )+. Step 5: In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2-fluoro-4-methyl-phenyl) -piperidine- 1 - carboxylic acid tert-butγ\ ester was prepared (3S,4S) or (3R,4R)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[ 4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 430.4 ([M+H, ICl] )+.
Step 6: In analogy to example 1, step 3, from (3S,4S) or (3R,4R)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R)-1- (3-chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-[4-(5-chloro- 2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 604.1 ([M+H, ICl] )+;
[α]D = + 14.03 (c= 0.442 g/100 mL, CHCl3).
Example 59
[(3S,4S) or (3R,4R)-l-(2-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2- chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R)-l-(2-chloro- benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 604.1 ([M+H, 1C1])+; [α]D = - 8.8 (c= 0.659 g/100 mL, CHCl3).
Example 60
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2- (trifluoromethyl)benzenesulfonyl chloride was prepared (3S,4S)or (3R,4R)-[4-(5-chloro- 2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4-methyl-phenyl)-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 638.3 ( [M+H, 1C1])+; [α]D = - 13.63 (c= 0.477 g/100 mL, CHCl3).
Example 61 (3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl] -methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared (3S,4S) or (3R,4R)-[4-(5- chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4-methyl-phenyl)-l-(pyridine-3- sulfonyl)-piperidin-3-yl] -methanone as a white foam, MS: 571.3 ( [M+H, ICl] )+; [α]o = + 0.67 (c= 0.446 g/100 mL, CHCl3).
Example 62 (3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(propane-2-sulfonyl)-piperidin-3-yl] -methanone
In analogy to example 1, step 3, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-(2-fluoro-4-methyl-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- propanesulfonyl chloride was prepared (3S,4S) or (3R,4R)-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] - [4- (2-fluoro-4-methyl-phenyl) - 1 - (propane-2-sulfonyl) - piperidin-3-yl] -methanone as a white foam, MS: 536.4 ( [M+H, ICl] )+; [α]D = - 16.22 (c= 0.746 g/100 mL, CHCl3).
Example 63
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2- methyl-phenyl) -piperazin- 1-yl] -methanone
Step 1: In analogy to example 52, steps 2-3, from (3R,4R)-4-phenyl-piperidine-l,3- dicarboxylic acid 1-tert-butyl ester (CAS Reg. No.: [197900-84-8]) was prepared (3S,4S)- 4-phenyl-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester as an off-white solid, MS: 304.3 (M-H])".
Step 2: In analogy to example 1, step 1, from 3S,4S)-4-phenyl-piperidine-l,3-dicarboxylic acid 1-tert-butyl ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-phenyl-piperidine- 1-carboxylic acid tert-butyl ester (Cas Reg. No. [652971-20-5]) as a white foam, MS: 500.5 ([M+H, 1C1])+.
Step 3: In analogy to example 22, step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butyl ester and l-(5- chloro-2-methylphenyl)-piperazine was prepared [4-(5-chloro-2-methyl-phenyl)- piperazin-l-yl]-((3S,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride as a white foam, MS: 400.5 ([M+H, ICl] )+.
Step 4: In analogy to example 1, step 3 using iPr2NEt as base and CH2Cl2 as solvent, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-phenyl-piperidin-3-yl)- methanone hydrochloride and 3-chlorobenzene-sulfonyl chloride was prepared [(3S,4R)- l-(3-chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)- piperazin-l-yl]-methanone as a white foam, MS: 572.15 ([M+H, 1C1])+.
Example 64 [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-phenyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 606.2 ( [M+H, ICl] )+.
Example 65
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-phenyl-l-(pyridine-3- sulfonyl)-piperidin-3-yl]-methanone In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-phenyl-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 539.3 ([M+H, 1C1])+.
Example 66
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone
Step 1: In analogy to example 46, step 1, from 4-o-tolyl-5,6-dihydro-2H-pyridine-l,3- dicarboxylic acid l-tert-butyl ester using [Ru(OAc)2((S)-(BITIANP))] as catalyst for the enantioselective hydrogenation was prepared (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-butyl ester as a white foam, MS: 318.2 ( [M-H])". Step 2: In analogy to example 52, steps 2-3, from (3R,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester was prepared (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester as a white solid, MS: 318.4 ([M-H])".
Step 3: In analogy to example 1, step 1, from (3S,4R)-4-o-tolyl-piperidine-l,3- dicarboxylic acid l-tert-buty\ ester and l-(5-chloro-2-methylphenyl)-piperazine was prepared (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)-piperazine-l-carbonyl]-4-o-tolyl- piperidine-1-carboxylic acid tert-butγ\ ester as a white foam, MS: 512.5 ([M+H])+.
Step 4: In analogy to 22 step 4, from (3S,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-butγ\ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4R)-4-o-tolyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 512.5 ( [M+H, 1C1])+.
Step 5: In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4R)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 586.1 ([M+H, ICl] )+.
Example 67
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-o-tolyl-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl]-methanone In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4R)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-4-o-tolyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 620.3 ( [M+H, ICl] )+.
Example 68
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(pyridine-3-sulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-
((3S,4R)-4-o-tolyl-piperidin-3-yl) -methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4R)-l-(pyridine-3-sulfonyl)-4-o-tolyl-piperidin-3-yl]-methanone as a white foam, MS: 553.2 ([M+H, 1C1])+.
Example 69
[(3S,4R) or (3R,4S) -l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone
Step 1: In analogy to example 46, step 1 from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty\ ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2,4-difluorophenylzinc bromide was prepared 4-(2,4-difluoro- phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty\ ester as a light yellow oil, MS: 354.2 (M+H) +.
Step 2: In analogy to example 46, step 2, from 4- (2,4-difluoro-phenyl) -5, 6-dihydro-2ff- pyridine-l,3-dicarboxylic acid 1-terf-butyl ester 3-methyl ester was prepared 4-(2,4- difluoro-phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty\ ester as a white solid, 338.1 (M-H)". Step 3: In analogy to example 46, step 3, from 4- (2,4-difluoro-phenyl) -5, 6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-buty\ ester using [Ru(OAc)2((S)-(BITIANP))] as catalyst for the enantioselective hydrogenation was prepared (3R,4R) or (3S,4S)-4-(2,4- difluoro-phenyl)-piperidine-l,3-dicarboxylic acid l-tert-buty\ ester as white solid, MS: 340.1 ([M-H])"; [α]D = + 61.90 (c= 0.806 g/100 mL, CHCl3).
Step 4: In analogy to example 52, steps 2-3, from (3R,4R) or (3S,4S)-4-(2,4-difluoro- phenyl)-piperidine-l,3-dicarboxylic acid l-tert-buty\ ester was prepared (3S,4R) or (3R,4S) -4-(2,4-difluoro-phenyl)-piperidine-l,3-dicarboxylic acid l-tert-buty\ ester as an off-white foam, MS: 340.4 ( [M-H])"; [α]D = - 8.11 (c= 0.271 g/100 mL, CHCl3).
Step 5: In analogy to example 1, step 1, from (3S,4R) or (3R,4S)-4-(2,4-difluoro-phenyl)- piperidine-l,3-dicarboxylic acid l-tert-buty\ ester and l-(5-chloro-2-methylphenyl)- piperazine was prepared (3S,4R) or (3R,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-butγ\ ester as a white foam, MS: 534.2 ( [M+H, 1C1])+.
Step 6: In analogy to example 22, step 4, from (3S,4R) or (3R,4S)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-butγ\ ester was prepared (3S,4R) or (3R,4S)-[4-(5-chloro-2-methyl-phenyl)- piperazin-1-yl] - [4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride as crude product, MS: 434.3 ([M+H, ICl] )+.
Step 7: In analogy to example 63, step 4, from (3S,4R) or (3R,4S)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[-4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4R) or (3R,4S)-1- (3-chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2- methyl-phenyl)-piperazin-l-yl] -methanone as a white foam, MS: 607.1 ( [M+H, ICl] )+; [α]D = - 66.8 (c= 0.434 g/100 mL, CHCl3).
Example 70
(3S,4R) or (3R,4S)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2,4-difluoro- phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from (3S,4R) or (3R,4S)-[4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared (3S,4R) or (3R,4S)-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(2,4-difluoro- phenyl)-l -(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone as a white foam, MS: 575.4 ( [M+H, ICl] )+; [α]D = - 66.76 (c= 0.454 g/100 mL, CHCl3).
Example 71
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone
Step 1: In analogy to example 1, step 1, from (3S,4S)-4-phenyl-piperidine-l,3- dicarboxylic acid 1-tert-butyl ester (CAS Reg. No.: [197900-77-9]) and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butγ\ ester as a white foam, MS: 498.5 ([M+H, ICl] )+.
Step 2: In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-phenyl-piperidine-l-carboxylic acid tert-butγ\ ester was prepared [4-(5-chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-phenyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 398.4 ( [M+H, ICl] )+. Step 3: In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin- l-yl]-((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-phenyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 572.2 ([M+H, ICl] )+.
Example 72 [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-phenyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 606.0 ( [M+H, ICl] )+.
Example 73
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(pyridine-3- sulfonyl)-piperidin-3-yl]-methanone In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-phenyl-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 539.2 ([M+H, 1C1])+.
Example 74
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(propane-2- sulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and 2-propanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl- l-(propane-2-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 504.1 ( [M+H, ICl] )+.
Example 75
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-phenyl- piperidin-3-yl)-methanone In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-phenyl-piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l- methanesulfonyl-4-phenyl-piperidin-3-yl)-methanone as a white foam, MS: 476.1 ( [M+H, ICl] )+.
Example 76
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone
Step 1: In analogy to example 1, step 1 , from (3S,4S)-4-o-tolyl-piperidine-l,3- dicarboxylic acid 1-terf-butyl ester (example 46, step 3) and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-butγ\ ester as a white foam, MS: 512.3 ([M+H, ICl] )+.
Step 2: In analogy to example 22, step 4, from (3S,4S)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine-l-carbonyl]-4-o-tolyl-piperidine-l-carboxylic acid tert-butγ\ ester was prepared [4-(5-chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S) -4-o-tolyl-piperidin-3- yl)-methanone hydrochloride as crude product, MS: 412.5 ( [M+H, ICl] )+.
Step 3: In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin- l-yl]-((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 3-chlorobenzene- sulfonyl chloride was prepared [(3S,4S)-l-(3-chloro-benzenesulfonyl)-4-o-tolyl- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 586.2 ([M+H, ICl] )+.
Example 77
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-o-tolyl-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and 2-(trifluoromethyl)- benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S)-4-o-tolyl-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl] -methanone as a white foam, MS: 620.5 ([M+H, ICl] )+.
Example 78 [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-l-(pyridine-3-sulfonyl)-4-o- tolyl-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-
((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-
[(3S,4S)-l-(pyridine-3-sulfonyl)-4-o-tolyl-piperidin-3-yl]-methanone as a white foam,
MS: 553.2 ([M+H, 1C1])+.
Example 79
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-o-tolyl- piperidin-3-yl)-methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- ((3S,4S)-4-o-tolyl-piperidin-3-yl)-methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-((3S,4S)-l- methanesulfonyl-4-o-tolyl-piperidin-3-yl) -methanone as a white foam, MS: 490.2 ( [M+H, ICl] )+.
Example 80
[(3S,4S) or (3R,4R) -l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-2-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl] -methanone
Step 1: In analogy to example 46, steps 1-2, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid l-tert-buty\ ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 4-fluoro-6-methylphenylzinc bromide (previously prepared from 4-fluoro-6-methylphenylmagnesium bromide and zinc chloride) was prepared 4- (4-fluoro-2-methyl-phenyl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-terf-butyl ester as a white solid, MS: 334.3 (M-H])".
Step 2: In analogy to example 46, step 3, from 4-(4-fluoro-2-methyl-phenyl)-5,6- dihydro-2H-pyridine-l,3-dicarboxylic acid l-tert-buty\ ester using [Ru(OAc)2((R)-(2- furyl) -MeOBIPHEP)] as catalyst for the enantioselective hydrogenation was prepared (3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidine-l,3-dicarboxylic acid l-tert- butyl ester as a white foam, MS: 336.2 (M-H])"; [α]D = - 52.53 (c= 0.643 g/100 mL, CHCl3). Step 3: In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl- phenyl)-piperidine-l,3-dicarboxylic acid 1-terf-butyl ester and l-(5-chloro-2- methylphenyl)-piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl- phenyl) -piperazine- 1 -carbonyl] -4- (4-fluoro-2-methyl-phenyl) -piperidine- 1 -carboxylic acid tert-butyl ester as a white foam, MS: 530.2 ( [M+H, ICl] )+.
Step 4: In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (4-fluoro-2-methyl-phenyl) -piperidine- 1 - carboxylic acid tert-butγ\ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 430.4 ([M+H, ICl] )+.
Step 5: In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin- l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydro-chloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R)- l-(3-chloro-benzenesulfonyl)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 604.0 ([M+H, 1C1])+; [α]D = - 32.13 (c= 0.426 g/100 mL, CHCl3).
Example 81
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2-(trifluoromethyl)benzenesulfonyl chloride was prepared [4-(5-chloro-2- methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2-methyl-phenyl)-l-(2- trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 638.2 ( [M+H, ICl] )+; [α]D = - 60.75 (c= 0.423 g/100 mL, CHCl3).
Example 82
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2- methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2-methyl-phenyl)-l- (pyridine-3-sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 571.2 ( [M+H, ICl] )+; [α]D = - 49.92 (c= 0.535 g/100 mL, CHCl3).
Example 83
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)- l-methanesulfonyl-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(4-fluoro-2-methyl-phenyl)-piperidin-3-yl] -methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(4-fluoro-2-methyl-phenyl)-l- methanesulfonyl-piperidin-3-yl] -methanone as a white foam, MS: 508.3 ( [M+H, ICl] )+; [α]D = - 77.86 (c= 0.434 g/100 mL, CHCl3).
Example 84
[(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-methanone
Step 1: In analogy to example 46, step 1, from 4-trifluoromethanesulfonyloxy-5,6- dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester 3-methyl ester (CAS Reg. No. [161491-25-4]) and 2,4-difluorophenylzinc bromide was prepared 4-(2,4-difluoro- phenyl)-5,6-dihydro-2ff-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester 3-methyl ester as a light yellow oil, MS: 354.2 ( [M+H] )+.
Step 2: In analogy to example 46, step 2, from 4-(2,4-difluoro-phenyl)-5,6-dihydro-2ff- pyridine-l,3-dicarboxylic acid l-tert-buty\ ester 3-methyl ester was prepared 4-(2,4- difluoro-phenyl)-5,6-dihydro-2H-pyridine-l,3-dicarboxylic acid 1-ferf-butyl ester as a white solid, MS: 338.0 (M-H])".
Step 3: In analogy to example 46, step 3, from 4-(2,4-difluoro-phenyl)-5,6-dihydro-2H- pyridine- 1,3-dicarboxylic acid l-tert-butyl ester using [Ru(OAc)2((S)-(BITIANP))] as catalyst for the enantioselective hydrogenation was prepared (3S,4S) or (3R,4R)-4-(2,4- difluoro-phenyl)-piperidine-l,3-dicarboxylic acid l-tert-buty\ ester as a white a white solid, MS: 340.1 (M-H])"; [α]D = - 61.33 (c= 0.473 g/100 mL, CHCl3).
Step 4: In analogy to example 1, step 1, from (3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)- piperidine-l,3-dicarboxylic acid 1-ferf-butyl ester and l-(5-chloro-2-methylphenyl)- piperazine was prepared (3S,4S) or (3R,4R)-3-[4-(5-chloro-2-methyl-phenyl)- piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-butγ\ ester as a white foam, MS: 534.2 ( [M+H, 1C1])+.
Step 5: In analogy to example 22, step 4, from (3S,4S) or (3R,4R)-3-[4-(5-chloro-2- methyl-phenyl) -piperazine- 1 -carbonyl] -4- (2,4-difluoro-phenyl) -piperidine- 1 -carboxylic acid tert-butγ\ ester was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride as crude product, MS: 434.5 ([M+H, ICl] )+.
Step 6: In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 3-chlorobenzenesulfonyl chloride was prepared [(3S,4S) or (3R,4R) - l-(3-chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-[4-(5-chloro-2- methyl-phenyl)-piperazin-l-yl]-methanone as a white foam, MS: 608.0 ( [M+H, ICl] )+; [α]D = + 10.71 (c= 0.392 g/100 mL, CHCl3).
Example 85
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro- phenyl)-l-(2-trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and 2-(trifluoromethyl)benzenesulfonyl chloride was prepared [4-(5-chloro-2-methyl- phenyl) -piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-l-(2- trifluoromethyl-benzenesulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 642.3 ( [M+H, ICl] )+; [α]D = - 22.86 (c= 0.442 g/100 mL, CHCl3).
Example 86
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro- phenyl)- l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone
In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl]-methanone hydrochloride and pyridine-3-sulfonyl chloride hydrochloride was prepared [4-(5-chloro-2-methyl- phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-l-(pyridine-3- sulfonyl)-piperidin-3-yl]-methanone as a white foam, MS: 575.3 ( [M+H, ICl] )+; [α]D = - 5.09 (c= 0.746 g/100 mL, CHCl3). Example 87
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro- phenyl)- l-methanesulfonyl-piperidin-3-yl] -methanone
In analogy to example 63, step 4, from 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and methanesulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l- yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro-phenyl)-l-methanesulfonyl-piperidin-3-yl]- methanone as a white foam, MS: 512.1 ([M+H, 1C1])+; [α]D = - 44.38 (c= 0.388 g/100 mL, CHCl3).
Example 88
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R) -4-(2,4-difluoro- phenyl)-l-(propane-2-sulfonyl)-piperidin-3-yl] -methanone
In analogy to example 63, step 4, 4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro-phenyl)-piperidin-3-yl] -methanone hydrochloride and 2- propane sulfonyl chloride was prepared [4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl]- [(3S,4S) or (3R,4R) -4-(2,4-difluoro-phenyl)-l-(propane-2-sulfonyl)-piperidin-3-yl]- methanone as a white foam, MS: 540.3 ([M+H, ICl] )+; [α]D = - 36.27 (c= 0.623 g/100 mL, CHCl3).
Example A
Film coated tablets containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per tablet
Kernel:
Compound of formula (I) 10.0 mg 200.0 mg
Microcrystalline cellulose 23.5 mg 43.5 mg
Lactose hydrous 60.0 mg 70.0 mg
Povidone K30 12.5 mg 15.0 mg Sodium starch glycolate 12.5 mg 17.0 mg
Magnesium stearate 1.5 mg 4.5 mg
(Kernel Weight) 120.0 mg 350.0 mg
Film Coat:
Hydroxypropyl methyl cellulose 3.5 mg 7.0 mg
Polyethylene glycol 6000 0.8 mg 1.6 mg
Talc 1.3 mg 2.6 mg
Iron oxyde (yellow) 0.8 mg 1.6 mg
Titan dioxide 0.8 mg 1.6 mg
The active ingredient is sieved and mixed with microcristalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidon in water. The granulate is mixed with sodium starch glycolate and magesiumstearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution / suspension of the above mentioned film coat.
Example B
Capsules containing the following ingredients can be manufactured in a conventional manner:
Ingredients Per capsule
Compound of formula (I) 25.0 mg
Lactose 150.0 mg
Maize starch 20.0 mg
Talc 5.0 mg The components are sieved and mixed and filled into capsules of size 2.
Example C
Injection solutions can have the following composition:
Compound of formula (I) 3.0 mg
Polyethylene Glycol 400 150.0 mg
Acetic Acid q.s. ad pH 5.0
Water for injection solutions ad 1.0 ml
The active ingredient is dissolved in a mixture of Polyethylene Glycol 400 and water for injection (part). The pH is adjusted to 5.0 by Acetic Acid. The volume is adjusted to 1.0 ml by addition of the residual amount of water. The solution is filtered, filled into vials using an appropriate overage and sterilized.
Example D
Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:
Capsule contents
Compound of formula (I) 5.0 mg
Yellow wax 8.0 mg
Hydrogenated Soya bean oil 8.0 mg
Partially hydrogenated plant oils 34.0 mg
Soya bean oil 110.0 mg
Weight of capsule contents 165.0 mg Gelatin capsule
Gelatin 75.0 mg
Glycerol 85 % 32.0 mg Karion 83 8.0 mg (dry matter)
Titan dioxide 0.4 mg
Iron oxide yellow 1.1 mg
The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example E
Sachets containing the following ingredients can be manufactured in a conventional manner:
Compound of formula (I) 50.0 mg
Lactose, fine powder 1015.0 mg
Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
Sodium carboxymethyl cellulose 14.0 mg
Polyvinylpyrrolidon K 30 10.0 mg
Magnesiumstearate 10.0 mg
Flavoring additives 1.0 mg
The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidon in water. The granulate is mixed with magnesiumstearate and the flavouring additives and filled into sachets.

Claims

Claims
1. Compounds of formula (I)
Figure imgf000077_0001
wherein
X is N or CH;
Y is N or CH;
R is lower-alkyl, lower-alkoxy-lower-alkyl, halogen-lower-alkyl, lower- alkenyl, cycloalkyl, cycloalkyl-lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl- lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower- alkoxy, fluoro-lower-alkyl and fluoro-lower-alkoxy;
R is lower-alkyl, fluoro-lower-alkyl, lower-alkoxy-lower-alkyl, cycloalkyl, cycloalkyl- lower-alkyl, aryl, aryl-lower-alkyl, heterocyclyl, heterocyclyl-lower-alkyl, heteroaryl or heteroaryl-lower-alkyl, wherein a cycloalkyl, aryl, heterocyclyl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro- lower-alkyl, fluoro-lower-alkoxy, lower-alkoxy-carbonyl and phenyl;
R3 is aryl or heteroaryl, which aryl or heteroaryl can optionally be substituted with 1 to 5 substituents independently selected from the group consisting of halogen,
CN, lower-alkyl, fluoro-lower-alkyl, lower-alkoxy and fluoro-lower-alkoxy;
R4, R5, R6, R7, R8, R9, R10 and R11 independently from each other are hydrogen or lower- alkyl, or
R4 and R5 are bound together, or R6 and R7 are bound together, or R8 and R9 are bound together, or R10 an R11 are bound together, to form a ring together with the carbon atom to which they are attached, and -R4-R5-, -R6-R7-,-R8-R9- and/or -R10- R11- is -(CH2W;
and pharmaceutically acceptable salts thereof.
2. Compounds according to claim 1, wherein X is N.
3. Compounds according to claim 1, wherein X is CH.
4. Compounds according to any of claims 1 - 3, wherein Y is N.
5. Compounds according to any of claims 1 - 4, wherein R1 is lower-alkyl, aryl or aryl-lower-alkyl, wherein aryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen and lower-alkyl.
6. Compounds according to any of claims 1 - 5, wherein R is lower-alkyl or phenyl, which phenyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl.
7. Compounds according to any of claims 1 - 6, wherein R1 is n-butyl, phenyl, 4-fluoro-2-methyl-phenyl, 2-methyl-phenyl, 4-fluoro-phenyl, 2-fluoro-4-methyl- phenyl or 2,4-difluoro-phenyl.
8. Compounds according to any of claims 1 - 7, wherein R is lower-alkyl, aryl or heteroaryl selected from the group consisting of isoxazolyl, quinolinyl, thiophenyl and pyridinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl, lower-alkoxy, fluoro-lower-alkyl, lower-alkoxy-carbonyl and phenyl.
9. Compounds according to any of claims 1 - 8, wherein R2 is lower-alkyl, phenyl or heteroaryl selected from the group consisting of quinolinyl and pyridinyl, which phenyl or heteroaryl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen, lower-alkoxy and fluoro- lower-alkyl.
10. Compounds according to any of claims 1 - 9, wherein R2 is methyl, isopropyl, 3-methoxy-phenyl, 3-chloro-phenyl, 2-trifluoromethyl-phenyl, quinoline-8-yl or pyridin-3-yl.
11. Compounds according to any of claims 1 - 10, wherein R3 is aryl or a heteroaryl selected from the group consisting of pyridinyl and pyrazinyl, which aryl or heteroaryl is optionally substituted with 1 to 3 substituents independently selected from the group consisting of halogen, lower-alkyl and fluoro-lower-alkyl.
12. Compounds according to any of claims 1 - 11, wherein R3 is phenyl or pyrazinyl, which phenyl or pyrazinyl is optionally substituted with 1 to 2 substituents independently selected from the group consisting of halogen and lower-alkyl.
13. Compounds according to any of claims 1 - 12, wherein R3 is 2,5-dimethyl- phenyl, 2-methyl-5-chloro-phenyl, 2,5-dichloro-phenyl or 3,6-dimethyl-pyrazin-2-yl.
14. Compounds according to any of claims 1 - 13, wherein R4, R5, R6, R7, R8, R9, R10 and R11 are hydrogen.
15. Compounds according to any of claims 1 - 14, selected from the group consisting of
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(3-methoxy- benzenesulfonyl) -piperazin-2-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -[4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone, (-)-[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl]- [4-
(2,5-dichloro-phenyl) -piperazin- 1-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(4-o-tolyl- piperazin- 1 -yl) -methanone,
[4-(2,5-Dichloro-phenyl) -piperazin- 1-yl]- [4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l- phenyl-piperazin-2-yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
(-)- [ l-Benzyl-4-(3-methoxy-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin-1-yl] -methanone,
[ l-Benzyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Benzyl-4-(3,5-dimethyl-isoxazole-4-sulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-propyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-1-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-isobutyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-phenethyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone, [4-(4-Chloro-benzenesulfonyl)-l-pentyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Butyl-4-(4-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(4-Chloro-benzenesulfonyl)-l-phenyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin-1-yl] -methanone,
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone, [4-(2-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4- (naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(naphthalene- 1 -sulfonyl) -piperazin-2-yl] -methanone, [l-(4-Fluoro-2-methyl-phenyl)-4-(naphthalene-l-sulfonyl)-piperazin-2-yl]-[4-(3- trifluoromethyl-pyridin-2-yl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dichloro-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-
8-sulfonyl) -piperazin-2-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-
(quinoline-8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline-
8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dichloro-phenyl) -piperazin- 1-yl] - [4-(propane-2-sulfonyl)-l-o-tolyl-piperazin-2- yl] -methanone,
[4-(Biphenyl-4-sulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dichloro-phenyl)-piperazin-
1-yl] -methanone,
3-{3-[4-(2,5-Dichloro-phenyl)-piperazine-l-carbonyl]-4-o-tolyl-piperazine-l-sulfonyl}- thiophene-2-carboxylic acid methyl ester, [4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(3', 6'- dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl) -methanone,
[l-Benzyl-4-(3-chloro-benzenesulfonyl) -piperazin-2-yl] -(3', 6'-dimethyl-2,3, 5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
[4-(3-Chloro-phenyl)-piperidin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(propane-2- sulfonyl) -piperazin-2-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
Cis-[4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [-l-(3-methoxy-benzenesulfonyl) -4- phenyl-piperidin-3-yl] -methanone, [4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [(3S,4S)-1 -(3-methoxy-benzenesulfonyl) -4- phenyl-piperidin-3-yl] -methanone,
[Trans- l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[Trans-l-(3,5-Dimethyl-isoxazole-4-sulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5- dimethyl-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [(3S,4S)-1 -(3-methoxy-benzenesulfonyl) -4-o- tolyl-piperidin-3-yl] -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone, [4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl] -((3S,4S)-1 -methanesulfonyl-4-o-tolyl- piperidin-3-yl) -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-((3S,4S)-l-methanesulfonyl-4-phenyl- piperidin-3-yl) -methanone,
[(3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(2,5-dimethyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- l-yl]-[(3S,4R) -1 -(3-methoxy-benzenesulfonyl) -4-o- tolyl-piperidin-3-yl] -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-(4-fluoro-phenyl)-l-(2- trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1 -yl] -methanone,
[(3S,4R)-l-(2-Chloro-benzenesulfonyl)-4-(4-fluoro-phenyl)-piperidin-3-yl]-[4-(5- chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro-phenyl)-l-
(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone, [(3S,4S) or (3R,4R)-l-(2-Chloro-benzenesulfonyl)-4-(2-fluoro-4-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(propane-2-sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2- methyl-phenyl) -piperazin- 1 -yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- 1-yl]- [(3S,4R)-4-phenyl- l-(pyridine-3- sulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-o-tolyl-l-(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-l-(pyridine-3-sulfonyl)-4-o- tolyl-piperidin-3-yl]-methanone,
[(3S,4R) or (3R,4S) -l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl)-piperazin-l-yl] -methanone, (3S,4R) or (3R,4S)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2,4-difluoro- phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-phenyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S)-4-phenyl-l-(2-trifluoromethyl- benzenesulfonyl)-piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-[(3S,4S) -4-phenyl-l -(pyridine-3- sulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-[(3S,4S) -4-phenyl-l -(propane-2- sulfonyl) -piperidin-3-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S)- 1 -methanesulfonyl-4-phenyl- piperidin-3-yl) -methanone,
[(3S,4S)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-[(3S,4S) -4-o-tolyl-l -(2-trifluoromethyl- benzenesulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-[(3S,4S) -1 -(pyridine-3-sulfonyl) -4-o- tolyl-piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl) -piperazin- l-yl]-((3S,4S)- 1 -methanesulfonyl-4-o-tolyl- piperidin-3-yl) -methanone, [(3S,4S) or (3R.4R) -l-(3-Chloro-benzenesulfonyl)-4-(4-fluoro-2-methyl-phenyl)- piperidin-3-yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R.4R) -4-(4-fluoro-2- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)-l-(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(4-fluoro-2- methyl-phenyl)-l-methanesulfonyl-piperidin-3-yl] -methanone,
[(3S,4S) or (3R,4R)-l-(3-Chloro-benzenesulfonyl)-4-(2,4-difluoro-phenyl)-piperidin-3- yl]-[4-(5-chloro-2-methyl-phenyl) -piperazin- 1-yl] -methanone, [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro- phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R,4R)-4-(2,4-difluoro- phenyl)-l-(pyridine-3-sulfonyl)-piperidin-3-yl]-methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R.4R) -4-(2,4-difluoro- phenyl) - 1 -methanesulfonyl-piperidin-3-yl] -methanone, and
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R.4R) -4-(2,4-difluoro- phenyl) - 1 - (propane-2-sulfonyl) -piperidin-3-yl] -methanone, and pharmaceutically acceptable salts thereof.
16. Compounds according to any of claims 1 - 15, selected from the group consisting of
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(3-methoxy- benzenesulfonyl) -piperazin-2-yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl)-piperazin-2-yl]-[4-(2,5- dichloro-phenyl) -piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[4-(3-methoxy-benzenesulfonyl)-l-phenyl- piperazin-2-yl] -methanone, [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-[4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[ l-Butyl-4-(3-chloro-benzenesulfonyl)-piperazin-2-yl] - [4-(2,5-dimethyl-phenyl)- piperazin- 1 -yl] -methanone,
[4-(2,5-Dimethyl-phenyl)-piperazin-l-yl]-[l-(4-fluoro-2-methyl-phenyl)-4-(quinoline- 8-sulfonyl) -piperazin-2-yl] -methanone,
[4-(2,5-Dichloro-phenyl) -piperazin- 1-yl] - [4- (propane-2-sulfonyl) -1 -o-tolyl-piperazin-2- yl] -methanone,
[4-(3-Chloro-benzenesulfonyl)-l-(4-fluoro-2-methyl-phenyl) -piperazin-2-yl] -(3', 6'- dimethyl-2,3,5,6-tetrahydro-[l,2']bipyrazinyl-4-yl) -methanone, [4-(3-Chloro-benzenesulfonyl)-l-o-tolyl-piperazin-2-yl]-(3',6'-dimethyl-2,3,5,6- tetrahydro- [ 1,2'] bipyrazinyl-4-yl) -methanone,
[4-(2,5-Dimethyl-phenyl) -piperazin- 1-yl]- [(3S,4R)-1 -(3-methoxy-benzenesulfonyl) -4-o- tolyl-piperidin-3-yl] -methanone,
[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4R)-4-(4-fluoro-phenyl)-l- (pyridine-3-sulfonyl) -piperidin-3-yl] -methanone,
(3S,4S) or (3R,4R)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2-fluoro-4- methyl-phenyl)-l-(2-trifluoromethyl-benzenesulfonyl) -piperidin-3-yl] -methanone,
[(3S,4R)-l-(3-Chloro-benzenesulfonyl)-4-o-tolyl-piperidin-3-yl]-[4-(5-chloro-2-methyl- phenyl) -piperazin- 1 -yl] -methanone, (3S,4R) or (3R,4S)-[4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[4-(2,4-difluoro- phenyl)-! -(pyridine-3-sulfonyl) -piperidin-3-yl] -methanone, and [4-(5-Chloro-2-methyl-phenyl)-piperazin-l-yl]-[(3S,4S) or (3R.4R) -4-(2,4-difluoro- phenyl) - 1 -methanesulfonyl-piperidin-3-yl] -methanone, and pharmaceutically acceptable salts thereof.
17. A process for the manufacture of compounds of formula (I) as defined in any of claims 1 - 16, which process comprises
a) reacting a compound of formula (II)
Figure imgf000085_0001
with a compound of formula (III)
Figure imgf000085_0002
(Hi) ,
or
b) reacting a compound of formula (IV)
Figure imgf000085_0003
(IV) with a compound R2SO2Cl, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and Y are as defined in any of claims 1 - 16.
18. Compounds according to any of claims 1 - 16, when manufactured by a process according to claim 17.
19. Pharmaceutical compositions comprising a compound according to any of claims 1 - 16 and a pharmaceutically acceptable carrier and/or adjuvant.
20. Compounds according to any of claims 1 - 16 for use as therapeutic active substances.
21. Compounds according to any of claims 1 - 16 for use as therapeutic active substances for the treatment and/or prophylaxis of diseases which are modulated by LXR alpha and/or LXR beta agonists.
22. A method for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists, particularly for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/ improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease, which method comprises administering a compound according to any of claims 1 - 16 to a human being or animal.
23. The use of compounds according to any of claims 1 - 16 for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists.
24. The use of compounds according to any of claims 1 - 16 for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/ improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
25. The use of compounds according to any of claims 1 - 16 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of diseases which are modulated by LXR alpha and/or LXR beta agonists.
26. The use of compounds according to any of claims 1 - 16 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of increased lipid levels, increased cholesterol levels, low HDL-cholesterol, high LDL- cholesterol, atherosclerotic diseases, diabetes, non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis of the liver, fibrosis of the liver, psoriasis, Alzheimer's disease, impaired/improvable cognitive function, HIV, cancer, age related forms of macular degeneration, inherited forms of macular degeneration and/or Stargadt's disease.
27. The invention as hereinbefore defined.
PCT/EP2008/060213 2007-08-13 2008-08-04 Novel piperazine amide derivatives WO2009021868A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2010001742A MX2010001742A (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives.
BRPI0815479-1A2A BRPI0815479A2 (en) 2007-08-13 2008-08-04 PIPERAZINE STARK DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, METHOD FOR TREATMENT AND / OR PROPHYLAXY OF DISEASES AND PROCESS OF PRODUCTION OF COMPOUNDS
EP08786826A EP2188266B1 (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
CA2695088A CA2695088C (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
ES08786826T ES2393822T3 (en) 2007-08-13 2008-08-04 New piperazine-amide derivatives
JP2010520529A JP5220858B2 (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
AU2008288537A AU2008288537B2 (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
CN200880103083.XA CN101778831B (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
KR1020107005485A KR101171507B1 (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives
ZA2010/01061A ZA201001061B (en) 2007-08-13 2010-02-12 Novel piperazine amide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114219.4 2007-08-13
EP07114219 2007-08-13

Publications (2)

Publication Number Publication Date
WO2009021868A2 true WO2009021868A2 (en) 2009-02-19
WO2009021868A3 WO2009021868A3 (en) 2009-04-09

Family

ID=40298643

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/060213 WO2009021868A2 (en) 2007-08-13 2008-08-04 Novel piperazine amide derivatives

Country Status (17)

Country Link
US (1) US8288541B2 (en)
EP (1) EP2188266B1 (en)
JP (1) JP5220858B2 (en)
KR (1) KR101171507B1 (en)
CN (2) CN101778831B (en)
AR (1) AR067904A1 (en)
AU (1) AU2008288537B2 (en)
BR (1) BRPI0815479A2 (en)
CA (1) CA2695088C (en)
CL (1) CL2008002356A1 (en)
ES (1) ES2393822T3 (en)
MX (1) MX2010001742A (en)
PE (1) PE20090592A1 (en)
RU (1) RU2454412C2 (en)
TW (1) TWI364420B (en)
WO (1) WO2009021868A2 (en)
ZA (1) ZA201001061B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033353A2 (en) 2010-09-07 2012-03-15 서울대학교 산학협력단 Sesterterpene compounds and use thereof
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
US9637481B2 (en) 2012-03-02 2017-05-02 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
WO2017123568A2 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
WO2018053588A1 (en) 2016-09-21 2018-03-29 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
US9981913B2 (en) 2013-09-04 2018-05-29 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
US10047055B2 (en) 2013-09-04 2018-08-14 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
WO2022235091A1 (en) * 2021-05-07 2022-11-10 엠비디 주식회사 Novel heterocyclic compound and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172635B (en) * 2011-12-21 2016-04-27 上海医药工业研究院 Piperazine or piperidines, its salt, intermediate, preparation method and application

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965559A (en) 1994-09-26 1999-10-12 Zeneca Limited Aminoheterocyclic derivatives as antithrombotic or anticoagulant
WO2003099769A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Anilino liver x-receptor modulators
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
WO2005121093A1 (en) 2004-05-07 2005-12-22 Laboratoires Fournier S.A. Lxr receptor modulators
US20050288317A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2008119657A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Imidazolidinone derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US530238A (en) * 1894-12-04 Guard for lathes
DK350383A (en) 1982-08-27 1984-02-28 Hoffmann La Roche phosphorus compounds
ATE128140T1 (en) * 1989-05-18 1995-10-15 Hoffmann La Roche PHOSPHORUS COMPOUNDS.
JP3204668B2 (en) 1991-03-15 2001-09-04 エフ・ホフマン―ラ ロシユ アーゲー Chiral phosphine
US5256321A (en) 1992-07-10 1993-10-26 The Lubrizol Corporation Grease compositions
CN1164232A (en) * 1994-09-26 1997-11-05 曾尼卡有限公司 Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
DE69718177T2 (en) * 1996-08-14 2003-10-23 Astrazeneca Ab SUBSTITUTED PYRIMID DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATION
UA79286C2 (en) * 2002-06-29 2007-06-11 Zentaris Gmbh Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors
DE102005000666B3 (en) * 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidines, process for their preparation and their use as pharmaceuticals

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965559A (en) 1994-09-26 1999-10-12 Zeneca Limited Aminoheterocyclic derivatives as antithrombotic or anticoagulant
WO2003099769A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Anilino liver x-receptor modulators
WO2004076418A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
WO2005121093A1 (en) 2004-05-07 2005-12-22 Laboratoires Fournier S.A. Lxr receptor modulators
US20050288317A1 (en) 2004-06-24 2005-12-29 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2008119657A1 (en) 2007-03-30 2008-10-09 F. Hoffmann-La Roche Ag Imidazolidinone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BENNETT ET AL., EXPERT OPIN, THER., vol. 14, no. 7, 2004

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012033353A2 (en) 2010-09-07 2012-03-15 서울대학교 산학협력단 Sesterterpene compounds and use thereof
US9637481B2 (en) 2012-03-02 2017-05-02 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
EP4218935A1 (en) 2012-08-13 2023-08-02 The Rockefeller University Lxrbeta agonist for the treatment of cancer
EP3626309A1 (en) 2012-08-13 2020-03-25 The Rockefeller University Lxrbeta agonist for the treatment of cancer
US9981913B2 (en) 2013-09-04 2018-05-29 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
US10047055B2 (en) 2013-09-04 2018-08-14 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
US10246419B2 (en) 2013-09-04 2019-04-02 Ralexar Therapeutics, Inc. Liver X receptor (LXR) modulators
US11034657B2 (en) 2013-09-04 2021-06-15 Ellora Therapeutics, Inc. Liver X receptor (LXR) modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
WO2017123568A2 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
AU2017329111B2 (en) * 2016-09-21 2021-01-28 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
CN110234631B (en) * 2016-09-21 2023-02-28 维克特斯生物系统有限公司 Composition for treating hypertension and/or fibrosis
AU2017329111B9 (en) * 2016-09-21 2021-03-04 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
CN110234631A (en) * 2016-09-21 2019-09-13 维克特斯生物系统有限公司 For treating the composition of hypertension and/or fibrosis
US11053202B2 (en) 2016-09-21 2021-07-06 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
RU2752088C1 (en) * 2016-09-21 2021-07-22 Вектус Байосистемс Лимитед Compositions for treatment of hypertension and/or fibrosis
US11834417B2 (en) 2016-09-21 2023-12-05 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
WO2018053588A1 (en) 2016-09-21 2018-03-29 Vectus Biosystems Limited Compositions for the treatment of hypertension and/or fibrosis
EP3640243A1 (en) * 2016-09-21 2020-04-22 Vectus Biosystems Limited Piperazine derivatives for the treatment of hypertension and/or fibrosis
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
US11459292B2 (en) 2019-12-13 2022-10-04 Inspirna, Inc. Metal salts and uses thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
US11878956B2 (en) 2019-12-13 2024-01-23 Inspirna, Inc. Metal salts and uses thereof
WO2022235091A1 (en) * 2021-05-07 2022-11-10 엠비디 주식회사 Novel heterocyclic compound and use thereof

Also Published As

Publication number Publication date
KR20100043096A (en) 2010-04-27
BRPI0815479A2 (en) 2015-02-10
AU2008288537A1 (en) 2009-02-19
RU2454412C2 (en) 2012-06-27
TWI364420B (en) 2012-05-21
KR101171507B1 (en) 2012-08-07
JP2010535834A (en) 2010-11-25
ES2393822T3 (en) 2012-12-28
CN103772299A (en) 2014-05-07
US20090048264A1 (en) 2009-02-19
CN101778831B (en) 2014-08-20
WO2009021868A3 (en) 2009-04-09
CN101778831A (en) 2010-07-14
PE20090592A1 (en) 2009-05-03
MX2010001742A (en) 2010-03-10
ZA201001061B (en) 2010-11-24
RU2010108943A (en) 2011-09-20
AR067904A1 (en) 2009-10-28
EP2188266A2 (en) 2010-05-26
TW200916463A (en) 2009-04-16
EP2188266B1 (en) 2012-10-17
US8288541B2 (en) 2012-10-16
CL2008002356A1 (en) 2009-05-29
AU2008288537B2 (en) 2011-03-24
JP5220858B2 (en) 2013-06-26
CA2695088C (en) 2013-03-12
CA2695088A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
CA2695088C (en) Novel piperazine amide derivatives
CA2681809C (en) Imidazolidinone derivatives
KR100979577B1 (en) 1-sulfonyl-piperidine-3-carboxylic acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus
US7741479B2 (en) Urea inhibitors of MAP kinases
CA2941581C (en) Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
AU2006236622B2 (en) Compositions of novel opioid compounds and method of use thereof
JPH072851A (en) Five-membered heterocyclic compounds, their preparation and medicinal composition containing these compounds
MX2007005765A (en) Gonadotropin releasing hormone receptor antagonists.
CA2877449A1 (en) 2-aminopyrazine derivatives as csf-1r kinase inhibitors
WO1996002503A1 (en) Novel compound having platelet aggregation inhibitor effect
KR20060009933A (en) Cyanofluoropyrrolidine derivative
KR20110101215A (en) Cysteine protease inhibitors
EA008479B1 (en) Pyrrolidine derivatives as oxytocin antagonists
CN101374811A (en) Novel dual nk2/nk3-antagonists, pharmaceutical compositions comprising them and processes for their preparations
WO1999052894A1 (en) Nitrogen-containing heterocyclic compounds having antiplatelet aggregation effect and medicinal use thereof
TWI643847B (en) Novel benzoazepine derivatives and their medical uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880103083.X

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2008786826

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 203595

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2695088

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12010500335

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2010520529

Country of ref document: JP

Ref document number: MX/A/2010/001742

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1032/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008288537

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20107005485

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010108943

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08786826

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2008288537

Country of ref document: AU

Date of ref document: 20080804

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0815479

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100212